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Prenatally detected chromosomal mosaicism complicates genetic counseling as there is  
variability in phenotypic outcome and available information pertaining to phenotypic 
consequences is limited.  The objective of this study was to identify the phenotypic effects of 
mosaicism that was diagnosed prenatally.  A total of 4,599 CVS specimens and 15,688 
amniocentesis specimens were collected between 1991 and 2005 and clinical information was 
reviewed for all mosaic cases.   
Of those procedures, 76 CVS specimens (1.65%) and 66 amniocentesis specimens 
(0.42%) indicated a mosaic result.  However, seven of the mosaic amniocentesis results were 
observed after a previous mosaic CVS result.  When these specimens were removed from the 
calculation, the incidence of mosaic amniocenteses was 0.38%.   Of the cases that had follow-up 
cytogenetic testing, CVS cases were found to have a true mosaicism rate of 23.6% while 
amniocentesis cases had a rate of 60.7%.  The rates of prenatally detected mosaicism and true 
fetal mosaicism for Magee-Womens Hospital are comparable to the rates reported in literature. 
This study found mosaic results involving trisomy for chromosomes 2, 7, 8, 9, 10, 12, 13, 15, 16, 
18, 20, 21, 22, X, and Y.  In addition, there was monosomy for chromosomes 21, 22, and X, 
tetraploidy, structural aberrations, and supernumerary marker chromosomes. However, no cases 
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of UPD were identified.  From this information, associations were made between the phenotypic 
outcomes observed in this study and those reported from previous studies.   
Based on the information provided from this study, it is apparent that phenotype can vary, 
even when the same abnormality is involved and that more information is needed regarding long 
term consequences of prenatally diagnosed mosaicism. The results of this study are important to 
public health because it provides additional data regarding the phenotypic results after prenatal 
diagnosis of mosaicism for various chromosome abnormalities and increases the understanding 
of the role of mosaicism in prenatal diagnosis, enabling more effective patient counseling. 
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1.0  INTRODUCTION 
The presence of two or more karotypically different cell lines in an individual arising from a 
single zygote is called chromosomal mosaicism. (Grati, 2006).  Many of the chromosomal 
abnormalities involving complete trisomies are lethal and do not survive to term unless a 
correction occurs early in embryonic life.  The correction from the presence of three copies of a 
chromosome to two copies of that chromosome may result in one chromosome from each parent 
(biparental origin) or both chromosomes from the same parent (uniparental origin).  This latter 
situation is termed uniparental disomy (UPD).  (Shaffer et al., 2001; Robinson, 2000).  Cases of 
UPD have been identified following the observation of prenatal mosaicism in chorionic villus 
sampling (CVS) and amniotic fluid.  The observation of an aneuploidy in the placenta at CVS 
and then a normal fetal karyotype in the amniotic fluid (termed confined placental mosaicism) is 
also recognized as a risk factor for UPD (Shaffer et al. 2001).   
This study reviewed the experience at the Pittsburgh Cytogenetics Laboratory to 
supplement our current understanding of the role of chromosomal mosaicism and uniparental 
disomy (UPD) in prenatal diagnosis and counseling.  The objective of this study was to identify 
the phenotypic effects of mosaicism that was diagnosed prenatally.  The following specific aims 
guided this study: 1. To review cases of mosaicism and uniparental disomy (UPD) detected by 
chorionic villus sampling (CVS) and amniocentesis performed during the time period 1991-2005 
to determine if rates of mosaicism and true fetal mosaicism correlate with literature; 2. To 
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evaluate follow-up information obtained through Magee-Womens Hospital including pregnancy 
outcome, pregnancy complications, abnormal characteristics, and additional testing; 3. To 
conduct further follow-up in order to obtain more information pertaining to long-term phenotypic 
effects; 4. To analyze the findings to attempt karyotype-phenotype correlations. 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 CHROMOSOMAL MOSAICISM 
 
Chromosomal mosaicism occurs when an individual, who has developed from a single fertilized 
egg, has two or more genetically distinct cell lines of differing karyotypes.  Usually, there will be 
some cells with a normal karyotype and other cells containing a numerical or structural 
chromosome abnormality (Gardner and Sutherland, 2004; Robinson, 2001).  It has been 
previously reported that mosaicism is detected in 1-2% of CVS procedures and true mosaicism is 
detected in about 0.1-0.3% of amniocentesis procedures (Grati et al., 2006; Hsu et al, 1996). 
Three different levels can be used to describe mosaicism detected prenatally.  Level I 
mosaicism involves the observation of a single abnormal cell.  This is usually a cultural artifact 
and considered pseudomosaicism.  Level II mosaicism is present when two or more cells with 
the same chromosome abnormality are seen in a culture from a single flask or in a single 
abnormal colony from an in situ culture.  The abnormality is not seen in colonies from other 
independent cultures.  Additional studies may be performed but these cases are almost always 
pseudomosaicism.  Lastly, Level III mosaicism is defined as the presence of two or more cells 
with the same chromosome abnormality that are distributed over two or more independent 
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cultures.  These cases are likely to represent true mosaicism, which is mosaicism that is present 
in placental and/or fetal tissues (Gardner and Sutherland 2004). 
The most common form of mosaicism found at prenatal diagnosis involves a trisomy, 
which is an additional chromosome, but mosaicism can occur with all types of chromosomal 
abnormalities (monosomy, polyploidy, structural changes, etc.).  Trisomy mosaicism can occur 
in two ways: 1.) an abnormal fertilized egg containing 47 chromosomes may lose the extra 
chromosome during cell division (meiotic nondisjunction error) or 2.) a typical zygote containing 
46 chromosomes may retain a duplicated chromosome during cell division (mitotic 
nondisjunction error).  The first scenario is often referred to as “trisomic rescue,” and if it occurs 
early in post-zygotic cell divisions and involves the cells destined to become the embryo, the 
originally abnormal chromosome content may result in a normal karyotype (Robinson, 2001; 
Shaffer et al., 2001). These cases are examples of confined placental mosaicism (CPM) because 
only the placenta is affected by chromosomal mosaicism.  
CPM is usually diagnosed when an aneuploidy is observed in the placenta at CVS and 
then a normal fetal karyotype is present in amniotic fluid. There are three types of CPM, which 
are categorized by the placental cell lineage exhibiting the abnormal cell line.  Mosaicism can be 
confined to the cytotrophoblast (type I), the chorionic stroma or mesenchyme (type II), or both 
(type III) (Kalousek & Vekemans, 1996).  CPM resulting from trisomic rescue generally 
involves high proportions of abnormal cells, especially if the correction occurs after the first cell 
division.   The majority of cells that are present during early development produce the 
cytotrophoblast so as a result, the cytotrophoblast will contain a significant number of trisomic 
cells with variable involvement of extra-embryonic mesenchyme.  Therefore, trisomic rescue is 
anticipated to show type I or III distribution.  Conversely, mitotic errors generally exhibit lower 
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percentages of abnormal cells, usually having type I or II distribution (Wolstenholme, 1996).  
Although the occurrence of CPM implies that the fetus is chromosomally normal, the possibility 
remains for a residual effect due to 1.) undetected or cryptic mosaic trisomy of the fetus; 2.) UPD 
of the fetus; and 3.) placental dysfunction as a consequence of a regional placental trisomy. 
 
2.2 CRYPTIC FETAL MOSAICISM 
Daniel et al. (2004) suggested that cryptic fetal mosaicism may be suspected if, in the absence of 
confirmatory karyotypic evidence, dysmorphic features characteristic of an aneuploidy that are 
unexplained by other means, such as CPM or UPD, are present.  It has been estimated from 
published data that about 10% of apparent CPM cases for rare trisomy (trisomy not involving 
chromosomes 13, 18, 20, or 21) may actually be cryptic fetal mosaics not detected in 
amniocytes.  In many cases, the cryptic mosaicism may be of limited clinical significance, but 
others may have obvious phenotypic effects (Daniel et al., 2004).   
 
2.3 UNIPARENTAL DISOMY 
Uniparental disomy is the abnormal situation in which both chromosomes in a pair are inherited 
from one parent, and the other parent’s chromosome for that pair is missing (Shaffer et al. 2001; 
Robinson, 2000).  UPD can result from chromosome loss in trisomy, gamete complementation, 
duplication in monsomy, and somatic recombination.  The presence of two copies of one parental 
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chromosome is called isodisomy while the presence of a pair of homologous chromosomes from 
one parent is heterodisomy.  Cases of UPD have been identified following the observation of 
prenatal or postnatal mosaicism, identification of a structurally abnormal chromosome, 
molecular investigation of recessive genetic disease, and a phenotype suggestive of a particular 
syndrome associated with imprinting (Shaffer, 2001).  CPM is also recognized as a risk factor for 
UPD because, theoretically, CPM resulting from trisomic rescue could result in uniparental 
inheritance in one-third of cases (Hall, 1990; Engel and Delozier-Blanchet, 1991).   
The first proven case of UPD was reported by Spence et al. (1988) and involved a 16-
year-old girl with short stature and cystic fibrosis, who had inherited two identical copies of a 
maternal chromosome 7.  A significant number of early reports of UPD in humans were 
ascertained due to the presence of autosomal recessive disease and in some cases, the 
identification of UPD resulted in the localization of a rare recessive disease (Ledbetter and 
Engel, 1995).  Other examples of conditions that have been inherited from a single carrier parent 
include osteogenesis imperfecta, spinal muscular atrophy, congenital chloride diarrhea, and 
Bloom syndrome (Hall, 1997).  However, recessive disease through UPD can occur for any 
recessive allele.  In addition, UPD for X-chromosomes can result in the transmission of X-linked 
recessive conditions, such as hemophilia, from a father to a son (Engel and DeLozier-Blanchet, 
1991).  
There are no apparent phenotypic effects from UPD for most chromosomes, but there are 
a few chromosomes that involve parent-specific imprinting and have clinically recognizable 
phenotypic effects when involved in UPD.  Genomic imprinting refers to the genetic marking of 
genes before fertilization so that one parental allele, depending on sex, is transcriptionally 
silenced (Hall, 1990).  Currently, maternally derived chromosomes 7, 14, and 15 and paternally 
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derived chromosomes 6, 11, 14, and 15 are the only examples of definite phenotypic effect due 
to UPD and imprinting.  Chromosomes 2, 16, and 20 are also being studied but it is unclear if 
their phenotypic effects are due to imprinting (Shaffer et al., 2001; Engel, 2003).    
Paternal UPD for chromosome 6 and paternal duplications of 6q are associated with 
transient neonatal diabetes mellitus, which is a rare form of diabetes that usually resolves by 6 
months of life.  It is thought that about 20% of cases are due to UPD (Shaffer et al., 2001; 
Gardner et al., 1998).  Russell-Silver syndrome is associated with prenatal and postnatal growth 
retardation with relative sparing of the head, triangular facies, and other dysmorphic features, 
limb and facial asymmetry, and clinodactyly.  About 10% of cases are due to maternal UPD7 
(Shaffer et al., 2001; Kotzot et al., 2000).    
Beckwith-Wiedemann syndrome (BWS) is a congenital overgrowth syndrome that is 
characterized by macroglossia, organomegaly, omphalocele, hemihypertrophy, genitourinary 
abnormalities, and a predisposition to embryonic tumors, including Wilms tumor.  About 85% of 
cases are sporadic, but familial cases have been reported with or without associated chromosome 
rearrangements.  Partial paternal UPD for the distal short arm of chromosome 11 occurs in 
approximately 20-25% of BWS.  In addition, studies have indicated that UPD occurs as a 
somatic event rather than a meiotic nondisjunction event (Shaffer et al., 2001; Catchpoole et al., 
1997).   
Specific features characterize Maternal and paternal UPD for chromosome 14.  
Individuals with maternal disomy 14 have short stature, hypotonia, hyperextensible joints, 
scoliosis, minor facial dysmorphic features, mild developmental delay, and precocious puberty.  
However, individuals with paternal disomy 14 have a more severe phenotype than those with 
maternal disomy 14.  Features include mental retardation, skeletal abnormalities that result in 
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short-limb dwarfism with narrow thorax, decreased survival due to respiratory difficulties, 
dysmorphic facies, and scoliosis.  Both conditions have been associated with Robertsonian 
translocations and isochromosomes and maternal disomy 14 has also been associated with 
mosaicism (Shaffer et al., 2001; Sutton and Shaffer, 2000). 
The best-studied examples of human genetic diseases due to imprinting are Prader-Willi 
syndrome (PWS) and Angelman syndrome (AS).  Prader-Willi syndrome results from an 
abnormal methylation pattern of 15q11-q13 due to paternal deletion, maternal UPD for 
chromosome 15, or imprinting center mutation.  About 25% of cases are due to maternal UPD 
and the majority of these cases represent heterodisomy as a result of maternal meiosis I 
nondisjunction.  PWS is characterized by low birth weight, early feeding problems, and 
hypotonia followed by severe obesity associated with hyperphagia.  Other features include 
developmental delay and/or mental retardation, short stature, behavior problems, and 
hypogonadism in males.  Angelman syndrome also involves abnormal methylation of 15q11-
15q13 but it can be caused by maternal deletion, paternal UPD, UBE3A gene mutation, or 
imprinting center defect.  About 3-5% of cases are due to paternal UPD and the majority of these 
cases show complete isodisomy, suggesting a monosomy 15 conception followed by duplication 
of a single paternal chromosome or by long arm isochromosome formation.  AS is characterized 
by severe mental retardation with absent speech, ataxic movements and gait, increased tone after 
infancy, seizures, and a happy disposition with paroxysmal laughter (Shaffer et al, 2001; 
EUCROMIC, 1999; L’Hermine et al., 2003). 
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2.4 PLACENTAL DYSFUNCTION 
It has been estimated that approximately 16-22% of pregnancies with CPM exhibit prenatal or 
perinatal complications.  These complications can include intrauterine growth retardation 
(IUGR), fetal loss, or poor perinatal outcome.  The effects of CPM on development may vary 
with the timing of the mosaicism, the type of chromosome abnormality, the proportion of 
abnormal cell line to normal cell line, and the tissues affected (Kalousek and Vekemans, 1996). 
Studies indicate that an adverse outcome is more likely when there are high levels of trisomy in 
term placenta (Wolstenholme et al., 1994).  Trisomy 16 is the most common trisomy observed in 
CPM.  There have been reports of malformation in cases of maternal disomy 16, which raised the 
possibility of imprinting, but studies have thus far neither conclusively supported nor excluded 
imprinting effects.  Studies have noted that the degree of trisomy 16 in the placenta seemed to 
correlate with IUGR of a chromosomally normal fetus independent of UPD status (Yong et al., 
2002).  Other chromosomes that have been implicated with pregnancy complications, such as 
prenatal and postnatal growth restriction, include 2, 7, and 22 (Wolstenholme, 1994).   
2.5 PREVIOUS STUDIES 
Cases of UPD are relatively rare; therefore, only a few cases have been identified.  Many studies 
involve only a small number of cases and have limited follow-up (Kotzot 2002).  The study that 
Thomas (1998) conducted analyzed pregnancy outcomes from CVS and amniocentesis 
procedures performed at Magee-Womens Hospital from 1991-1997 to determine the incidence of 
prenatally detected mosaicism and appropriate methods of pregnancy management.  Thomas 
recommended that further research in mosaicism and UPD be pursued and that long-term follow-
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up information on children with UPD was needed. This study reviewed all the cases of prenatally 
diagnosed mosaicism during 1991-2005 in order to improve our understanding of the mosaicism 
and UPD and to more effectively counsel patients. 
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3.0  METHDOLOGY 
3.1 STUDY DESIGN 
This was a retrospective study that included the analysis of patients who had previous prenatal 
diagnosis.  The study included women who had a CVS or amniocentesis procedure performed at 
Magee-Womens Hospital between the years 1991 to 2005 with an outcome involving 
chromosomal mosaicism and/or UPD.  All patients who had a cytogenetic report that listed the 
result of the CVS or amniocentesis as a mosaic were included.  Clinical information was 
reviewed for all cases, but only pregnancies that resulted in a live birth were considered for 
further follow-up. 
Reviewing outcomes from all CVS and amniocentesis procedures performed from 1991-
2005 identified cases of mosaicism from CVS and amniocentesis results.  Thomas (1998) had 
previously collected information pertaining to cases from 1991-1997.  Therefore, information 
pertaining to cases from 1998-2005 were obtained.  These outcomes, along with cytogenetic 
reports, were obtained from the Magee-Womens Hospital Genetics Information System (GIS).  
Medical records for these patients, obtained from patient files and the Magee-Womens Hospital 
Genetics Department’s registry of follow-up performed on all prenatal specimens, were then 
reviewed in order to gain more information about the pregnancy following prenatal diagnosis, 
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including delivery and follow-up clinic visits.  This information was collected for analysis and to 
determine who should be contacted for further follow-up.  
IRB approval was required in order to contact patients for further follow-up.  This 
process was quite time-consuming and approval was not obtained until the end of January of 
2006.  In addition, only a genetic counselor or physician who previously met with the patient 
could contact them and informed consent needed to be obtained before they could be 
interviewed.  Due to time limitations, patients had not been contacted as of March 25, 2006.  
However, modifications are being submitted in order to allow this study to continue under the 
direction of Urvashi Surti, Ph.D. 
Potential participants for follow-up were identified, and a genetic counselor or clinical 
geneticist with whom they had previously met will contact them to ask if they would participate 
in the study.  They will explain why the potential participants are being contacted and the 
purpose of the study.  If they do not wish to participate in the study, they were not contacted 
again. If they do wish to participate, they will be interviewed by phone.  The questions asked 
during the interview will pertain to complications that occurred during pregnancy and/or 
childbirth and the postnatal clinical information about the participant’s child.  People who agreed 
to participate will also be asked if the study investigators could view their child’s medical 
records as well as their records pertaining to the childbirth.  Two consent forms and a self-
addressed stamped envelope will be sent for the participant to review and sign.  Medical record 
review for this study will not take place until the signed consent forms are obtained.   
The data collected in this study was analyzed and correlations were made between 
specific chromosome abnormalities and their corresponding phenotypes.  Broader conclusions 
about karyotype-phenotype correlations were also made, along with recommendations for 
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counseling.  Information obtained after further follow-up will be added to current data and 
correlations will be adjusted accordingly. 
3.2 CHORIONIC VILLUS SAMPLING (CVS)  
Chorionic villus sampling procedures were performed either transcervically or transabdominally.  
Samples collected by catheter (transcervical) and by needle (transabdominal) were immediately 
placed in sterile media for transport to the laboratory. In order to minimize the possibility of 
maternal cell contamination, the villi were then cleaned by removing maternal decidua and blood 
clots with the guidance of a stereodissecting microscope.  The samples were then dissociated.  
First, they were placed in 15 ml conical centrifuge tubes and then they were incubated at 37°C 
for 30 minutes in 5 ml of a 0.25% trypsin solution.  Next, they were incubated for 30-45 minutes 
at 37°C in 4 ml of a collagenase solution.  Two types of media were then added and then the 
cells were spread onto glass coverslips.  Specimens were then incubated at 37°C with 5% CO2 
levels and 5% O2 levels.  The cells were then harvested when sufficient growth was achieved.  
This was either done by hand or by using TECAN or Genial, which are automated harvesting 
systems.  The coverslips were then attached to glass slides, placed on a slide warmer at 60°C for 
approximately one hour, and then incubated overnight in a 60°C oven.  Lastly, the specimens 
were prepared for analysis by Giemsa banding. 
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3.3 AMNIOCENTESIS 
Amniotic fluid samples were collected by standard methods and transported to the laboratory.  
They were then spun in 15 ml conical centrifuge tubes at 1000 rpms for 10 minutes.  Two types 
of media were then added to the pelleted cells and the cells were spread on glass coverslips.  
Specimens were then incubated at 37°C with 5% CO2 levels and 5% O2 levels. The cells were 
then harvested when sufficient growth was achieved.  This was either done by hand or by using 
TECAN or Genial.  The coverslips were then attached to glass slides, placed on a slide warmer at 
60°C for approximately one hour, and then incubated overnight in a 60°C oven.  Lastly, the 
specimens were prepared for analysis by Giemsa banding. 
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4.0  RESULTS 
4.1 TOTAL MOSAIC CASES 
A total of 4,599 CVS procedures were performed between 1991 and 2005.  Of those procedures, 
76 (1.65%) indicated a mosaic result.  This incidence is comparable to other reported figures and 
is broken down by year in Table 1. 
 
Table 1. Percentage of Mosaic CVS Results Per Year 
 
Year # of Mosaics Total # of CVS Specimens Percentage 
1991 2 67 2.99% 
1992 0 69 0.00% 
1993 2 197 1.02% 
1994 7 263 2.66% 
1995 14 317 4.42% 
1996 8 352 2.27% 
1997 6 355 1.69% 
1998 11 431 2.55% 
1999 5 389 1.29% 
2000 2 371 0.54% 
2001 4 324 1.23% 
2002 3 365 0.82% 
2003 4 375 1.07% 
2004 7 410 1.71% 
2005 1 314 0.32% 
Total 76 4599 1.65% 
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 There were 8 mosaic CVS specimens between 1993 and 1996 that showed a deleted 10q 
cell line.  It was hypothesized that these cases were most likely tissue culture artifacts due to 
growth factors and other chemicals added to the media to promote faster growth.  Therefore, 
these cases were excluded from the mosaic CVS data. 
 The individual cytogenetic results for the mosaic CVS cases are listed in Table 2, in 
addition to the reason for referral and outcome for each case. 
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Table 2. Cytogenetic Results for Mosaic CVS Cases 
 
Case Reason for Referral CVS Results Outcome
1 AMA 47,XY,+2[6]/46,XY[42]+ LB  
2 AMA 47,XY,+2[2]/46,XY[21]+ LB  
3 AMA 47,XX,+2[4]/46,XX[21]+ LB  
4 AMA 47,XX,+2[15]/46,XX[5] LB  
5 AMA 47,XX,+2[3]/46,XX[47] LB  
6 AMA 47,XY,+2[6]/46,XY[14] LB  
7 AMA 47,XX,+2[12]/46,XX[18] LB  
8 AMA 48,XX,+2,+7[12]/46,XX[38] LB 
9 AMA 47,XX,+7[16]/46,XX[4] LB  
10 AMA 48,XXX,+7[7]/46,XX[13] LB 
11 BTC 47,XX,+7[6]/46,XX[24] LB  
12 AMA 47,XY,+8[8]/46,XY[4]+ LB  
13 AMA 47,XY,+8[2]/46,XY[48] LB 
14 AMA, PP-T18 47,XY,+8[7]/46,XY[17] LB  
15 AMA 47,XY,+9[4]/46,XY[16]+ LB 
16 AMA 47,XY,+9[18]/46,XY[32] TA 
17 AMA 47,XY,+9[3]/46,XY[32] LB  
18 AMA, increased NT 47,XY,+10[18]/46,XY[4]+ LB  
19 AMA 47,XY,+10[5]/46,XY[45] LB  
20 AMA, PP-T18 47,XY,+10[13]/46,XY[37] SA 
21 AMA 47,XX,+12[26]/46,XX[14]+ LB  
22 AMA 47,XY,+13[7]/46,XY[43] LB  
23 AMA 47,XY,+15[32]/46,XY[21]+ LB  
24 AMA 47,XY,+15[4]/46,XY[26] N/A 
25 N/A 47,XY,+16+ LB 
26 AMA 47,XX,+16[19]/46,XX[2]+ TA 
27 AMA 48,XX,+16,+20[16]/46,XX[74] LB  
28 AMA 47,XX,+18[9]/46,XX[11] LB  
29 AMA 47,XX,+18[10]/46,XX[10] LB 
30 AMA, PP-47,XXY 46,X,+21[17]/47,XX,+21[33]+ TA 
31 N/A 47,XX,+22[9]/46,XX[41]+ N/A 
32 AMA 45,XX,-22[4]/46,XX[18] LB  
33 AMA 45,X/46,XX+ LB  
34 AMA 45,X[7]/46,XX[23] LB  
35 AMA 45,X[15]/46,XX[5] LB  
36 AMA 45,X[2]/46,XX[48]+ SA 
37 AMA 45,X[2]/46,XX[48]+ LB  
38 AMA 45,X[2]/46,XX[48]+ LB  
39 AMA 45,X[10]/46,XX[10] TA 
 
 
 
 
 17 
Table 2. (continued) 
 
 
40 AMA 45,X[7]/46,XX[43] SA 
41 AMA 45,X[7]/46,XX[43] LB  
42 AMA 45,X[5]/46,XY[45] LB  
43 AMA 45,X[9]/46,XY[21] LB  
44 AMA 45,X[2]/46,XY[48]+ LB  
45 AMA 45,X[2]/46,XY[48]+  LB  
46 AMA 45,X[8]/46,XY[12]+ LB  
47 AMA 47,XXY[11]/46,XY[39]+ LB 
48 AMA 47,XXY[37]/46,XY[13] LB  
49 AMA, FHx DS 47,XXY[12]/46,XY[18] LB  
50 AMA 47,XX,+mar[3]/46,XX[47]+ LB  
51 AMA 47,XX,+mar[3]/46,XX[48]+ LB  
52 AMA 47,XX,+mar[4]/46,XX[46]+ LB  
53 AMA 47,XX,+mar[2]/46,XX[48]+ LB  
54 AMA 47,XX,+mar[4]/46,XX[25]+ LB  
55 AMA 47,XY,+mar[2]/46,XY[20]+ LB  
56 AMA 47,XX,+mar[2]/46,XX[18]+ LB  
57 AMA, increased NT 47,XX,+mar[3]/46,XX[18]+ LB  
58 AMA 47,XY,+mar[8]/46,X,+mar[2]/46,XY[20]+ 
 - marker identified as 17 in origin LB  
59 AMA 45,X[13]/46,X,+mar[6]/46,XY[4]+ 
- marker identified as Y in origin LB  
60 AMA 47,XY,+mar(mat)[16]/46,XY[4] N/A 
61 AMA, PP-T16, T22 +mar 47,XY,+mar(mat)[15]/46,XY[5] LB  
62 AMA 46,XX/47,XX,+mar TA 
63 AMA 47,XY,+mar[8]/46,XY[12] LB  
64 AMA 92,XXXX[exact # not documented]/46,XX[20]+ SA 
65 AMA, BTC 92,XXXX[13]/46,XX[7] LB  
66 AMA 92,XXYY[41]/46,XY[11] LB  
67 AMA 46,XX,t(5;7)(p15.1;q34)[4]/46,XX[19]+ LB  
68 AMA 46,XX,der(5)t(5;?)(q35.1;?)[2]/46,XX[20]+ LB 
69 AMA 47,XX,+inv dup(8)(p23.1p12)[7]/46,XX[43] LB  
70 AMA, increased NT 46,XY,+9,der(13)t(9;13)(q10;q10)[3]/46,XY[18] P 
71 AMA 47,XX,+i(12p)[5]/46,XX[21]+ LB 
72 AMA 46,XX,del(13)(q22)[3]/46,XX[47]+ LB  
73 AMA, Abnormal u/s 46,XX,add(13)(p10).ish der(13)(wcp13+)[17]/ 
46,XX,der(13;13)(q10;q10),+13[3]+ TA 
74 AMA 47,XX,r(15)[6]/46,XX[44]+ LB  
75 AMA 47,XY,+inv dup(15)(p10)[18]/46,XY LB  
76 AMA 45,X[2]/46,X,i(Xq) TA 
+Previously reported in Thomas, 1998 
AMA-Advanced Maternal Age, NT-nuchal translucency, u/s-ultrasound, BTC-balanced translocation carrier, FHx-
family history, DS-Down syndrome, N/A-not available, LB-live birth, TA-therapeutic abortion, SA-spontaneous 
abortion, P-pregnant, PP-previous pregnancy, T22-Trisomy 22, T21-Trisomy 21, T18-Trisomy 18, T16-Trisomy 16 
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The majority of cases (96.1%) were referred because of advanced maternal age (35 years 
of age or older).  Other reasons for referral included an abnormal ultrasound (5.3%), previous 
pregnancy with a chromosome abnormality (5.3%), and a family history of a chromosome 
abnormality or balanced translocation (3.9%).  Some patients were referred for more than one 
reason, resulting in a total greater than 100%.  The reason for referral was not available for two 
cases. 
 The frequency of each type of chromosome abnormality, including the chromosome 
involved with each trisomy and monosomy, is depicted in Figure 1. 
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Figure 1.  Frequency of CVS Mosaics by Chromosome Abnormality 
 
A total of 15,688 amniocentesis specimens were analyzed between 1991 and 2005.  Of 
these, 66 (0.42%) indicated a mosaic result.  However, 7 of these mosaic amniocentesis results 
were observed after a previous mosaic CVS result.  When these specimens were removed from 
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the calculations, the incidence of mosaic amniocenteses became 0.38%.  Both of these 
percentages are comparable to other studies and are broken down by year in Table 3. 
 
 
Table 3. Percentage of Mosaic Amniocentesis Results Per Year 
 
Year # of Mosaics Total # of Amnios Percentage 
1991 5 1012 0.49% 
1992 3 1245 0.24% 
1993 3 1318 0.23% 
1994 2 1249 0.16% 
1994 w/o CVS referrals* 1 1249 0.08% 
1995 5 1433 0.35% 
1995 w/o CVS referrals* 3 1433 0.21% 
1996 9 1404 0.64% 
1996 w/o CVS referrals* 7 1404 0.50% 
1997 3 1286 0.23% 
1997 w/o CVS referrals* 2 1286 0.16% 
1998 4 1081 0.37% 
1999 2 1009 0.20% 
2000 7 1090 0.64% 
2001 8 968 0.83% 
2001 w/o CVS referrals* 7 968 0.72% 
2002 8 779 1.03% 
2003 3 703 0.43% 
2004 2 599 0.33% 
2005 2 512 0.39% 
Total 66 15688 0.42% 
Total w/o CVS referrals* 59 15688 0.38% 
*Amnios performed due to a mosaic CVS were taken out of the mosaic amnio data 
 
 The individual cytogenetic results for each of the mosaic amniocentesis cases are listed in 
Table 4 and also includes the reason for referral and outcome for each case. 
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Table 4. Cytogenetic Results for Mosaic Amniocentesis Cases 
 
Case Reason for Referral Amniocentesis Results Outcome
77 AMA 47,XX,+2[8]/46,XX[42] + N/A 
78 Abnormal u/s,  
Abnormal MMS-NTD 47,XX,+8[5]/46,XX[25] LB  
79 AMA, Abnormal MMS-T18, 
Abnormal u/s-Dandy Walker  47,XX,+9[9]/46,XX[13] TA 
80 N/A 47,XX,+12[2]/46,XX[48] + N/A 
81 AMA 47,XX,+13[3]/46,XX[62] LB 
82 Abnormal CVS 47,XY,+15/46,XY*+ LB  
83 Abnormal CVS 47,XX,+16[19]/46,XX[7]* + TA 
84 Abnormal u/s-choroid plexus cysts 47,XY,+18[46]/46,XY[4] + TA 
85 Abnormal u/s-cystic hygroma 47,XX,+18[18]/46,XX[2] N/A 
86 AMA 47,XX,+20[5]/46,XX[45] + LB  
87 AMA, Abnormal MMS-T21 47,XX,+20[6]/46,XX[11] + LB  
88 Abnormal u/s-short limbs, duodenal 
atresia 47,XY,+20[7]/46,XX[41] + N/A 
89 Abnormal MMS-T21 47,XX,+21[36]/46,XX[9] + LB  
90 Abnormal MMS-T21 47,XX,+21[35]/46,XX[14] + TA 
91 Abnormal MMS-T18 47,XX,+21[4]/46,XX[34] + LB 
92 AMA, PPL 47,XX,+21[4]/46,XX[40] + LB  
93 Abnormal MMS-T21 47,XX,+21[9]/46,XX[37] TA 
94 Abnormal u/s-increased NT 47,XY,+21[23]/46,XY[4] LB  
95 Abnormal MMS-T21 45,XY,-21[4]/46,XY[30] N/A 
96 N/A 45,X[9]/46,XX[36] + N/A 
97 Abnormal u/s-cystic hygroma 45,X[48]/46,XX[2] + SA 
98 AMA 45,X[15]/46,XX[35] + N/A 
99 PC w/ CHIME 45,X[5]/46,XX[25] + N/A 
100 AMA 45,X[7]/46,XX[8] + LB  
101 AMA 45,X[5]/46,XX[10] P 
102 AMA 45,X[6]/46,XX[19] P 
103 AMA 45,X[3]/46,XX[17] + LB  
104 Abnormal MMS-T21 45,X[33]/46,XX[17] + N/A 
105 AMA 45,X[10]/46,XX[16] LB  
106 AMA 45,X[4]/46,XX[16] LB  
107 AMA 45,X[10]/46,XX[32] LB  
108 Abnormal MMS-T21 45,X[8]/46,XX[8] LB  
109 Abnormal FTS-T21 45,X[5]/46,XX[10] TA 
110 AMA 45,X[5]/46,XX[27] LB 
111 AMA 45,X[22]/46,XX[3] N/A 
112 Abnormal MMS-T18 45,X[39]/46,XX[7] LB 
113 AMA 45,X[10]/46,XX[5] LB  
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Table 4. (continued) 
 
 
114 Abnormal MMS-T21 45,X[5]/46,XY[25] TA 
115 AMA,  
Abnormal u/s-choroid plexus cysts 45,X[3]/46,XY[22] LB  
116 Abnormal MMS-T21 45,X[15]/46,XY[35] LB  
117 Abnormal MSAFP 45,X[2]/46,XY[18] + N/A 
118 Abnormal MMS-T21 45,X[3]/46,XY[41] + LB 
119 AMA 47,XXX[5]/45,X[3]/46,XX[22] LB  
120 AMA 47,XYY[13]/45,X[12] + LB  
121 N/A 47,XXY/46,XY+ LB  
122 Abnormal CVS 47,XXY[5]/46,XY[40]* + LB 
123 Abnormal CVS 47,XXY[2]/46,XY[48]* LB  
124 AMA 47,XXY[5]/46,XY[20] LB  
125 AMA 47,XXY[6]/46,XY[34] N/A 
126 AMA, Abnormal MMS-T21 47,XYY[8]/46,XY[8] LB 
127 AMA 47,XX,+mar[5]/46,XX[40].ish  
der(22)(D14Z1/D22Z1+,wcp22+) N/A 
128 Abnormal MMS-T21 47,XX,+mar[44]/46,XX[6] 
-identified as 6 in origin LB  
129 Abnormal u/s-cardiac anomalies 47,XX,+mar[6]/46,XX[9] 
-identified as 7 in origin TA 
130 AMA 47,XX,+mar[10]/46,XX[5].ish  
inv dup(13)(p10) LB  
131 AMA 47,XY,+mar[6]/46,XY[28].ish  
dup(21)(q11.2) N/A 
132 Abnormal MMS-T21 45,X[27]/47,X,inv(Y)(p11q12),+mar[5] 
/46,XY[13] + LB  
133 Abnormal CVS 46,X,+mar[5]/46,XY[16].ish  
der(y)(wcp+)*+ LB  
134 AMA 46,XY,der(5)del(5)(p14.2)dup(5)(q14q22) 
t(5;14)(q13;q32)[9]/46,XY[31] N/A 
135 Abnormal CVS 47,XX,+i(12p)[1]/46,XX[62]* + LB 
136 Abnormal u/s-diaphragmatic hernia 47,XY,+i(12)(p10)[10]/46,XY[5] TA 
137 AMA 46,XY,der(13)t(13;?)[5]/46,XY[44] + TA 
138 Abnormal CVS 47,XY,+der(17)[6]/46,XY[68]* + LB  
139 AMA 46,X,i(Xq)[6]/46,XX[90] + N/A 
140 AMA 46,X,idic(Y)(q11.2)[9]/45,X[6] LB  
141 Abnormal MMS-T21 45,X[37]/46,X,psu idic (Y)(p11.32)[4] LB  
142 AMA, Abnormal u/s-increased NT 45,X[9]/46,X,i(Y)(p10)[6] LB  
*Mosaicism was also seen on CVS specimen
+Previously reported in Thomas, 1998 
AMA-Advanced Maternal Age, NT-nuchal translucency, u/s-ultrasound, N/A-not available, LB-live birth, TA-
therapeutic abortion, SA-spontaneous abortion, P-pregnant, PP-previous pregnancy, PPL-previous pregnancy loss,  
PC-previous child, T21-Trisomy 21, T18-Trisomy 18 
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The reason for referral for the majority of cases was also advanced maternal age (46.9%).  
However, there is a wider range of referral reasons for amniocentesis patients than CVS patients.  
Abnormal multiple marker and first trimester screens accounted for 30.3%, abnormal ultrasounds 
accounted for 16.7%, and abnormal CVS results accounted for 10.6%.  In addition, one patient 
had previous pregnancy losses and one had a previous child with a genetic disorder.  The reason 
for referral was not available for three cases and some of the patients were referred for more than 
one reason.  
The frequency of each type of chromosome abnormality, including the chromosome 
involved with each trisomy and monosomy, is depicted in Figure 2. Amniocentesis specimens 
obtained from CVS referral are included. 
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Figure 2. Frequency of Amniocentesis Mosaics by Chromosome Abnormality 
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4.2 MOSAIC CVS CASES 
Pregnancy outcome data was collected for 73 of 76 CVS patients (96.1%) and are listed in Table 
5.  Of these 73 CVS patients, four had a spontaneous abortion (5.4%) and seven had therapeutic 
abortions (9.6%).  The therapeutic abortions were performed because of the following results: 
47,XY,+9/46,XY, 47,XX,+16/46,XX, 46,X,+21/47,XX,+21, 45,X/46,XX, 46,XX/47,XX,+mar, 
45,X/46,X,i(Xq), and 46,XX,add(13)(p10)/46,XX,der(13;13)(q10;q10),+13.  Three of these 
cases (26, 30, and 73) were confirmed to be true mosaics by either follow-up amniocentesis or 
tissue analysis while two (16 and 62) were found to be confined to the placenta.  No further 
testing was performed for cases 39 and 76.  Of the spontaneous abortions, tissue analysis was 
normal for cases 36 and 64 and mosaic for case 40 while case 20 had no further testing 
performed.   Case 70 had not delivered as of March 25, 2006. 
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Table 5. Pregnancy Outcomes for Mosaic CVS Cases 
 
Case CVS Results Outcome Complications 
1 47,XY,+2[6]/46,XY[42]+ LB (8lb4oz) None 
2 47,XY,+2[2]/46,XY[21]+ LB (8lb2oz) None 
3 47,XX,+2[4]/46,XX[21]+ LB (8lb0oz) None 
4 47,XX,+2[15]/46,XX[5] LB (7lb15oz) None 
5 47,XX,+2[3]/46,XX[47] LB (6lb13oz) None 
6 47,XY,+2[6]/46,XY[14] LB (4lb10oz) preterm 36+ wks, early twin SA 
7 47,XX,+2[12]/46,XX[18] LB (7lb14oz) None 
8 48,XX,+2,+7[12]/46,XX[38] LB None 
9 47,XX,+7[16]/46,XX[4] LB (7lb10oz) None 
10 48,XXX,+7[7]/46,XX[13] LB None 
11 47,XX,+7[6]/46,XX[24] LB (9lb5oz) None 
12 47,XY,+8[8]/46,XY[4]+ LB (8lb14oz) pre-eclampsia 
13 47,XY,+8[2]/46,XY[48] LB PROM 21wks, neonatal death 
14 47,XY,+8[7]/46,XY[17] LB (5lb8oz) preterm 34+ wks 
15 47,XY,+9[4]/46,XY[16]+ LB None 
16 47,XY,+9[18]/46,XY[32] TA   
17 47,XY,+9[3]/46,XY[32] LB (7lb8oz) None 
18 47,XY,+10[18]/46,XY[4]+ LB (5lb13oz) None 
19 47,XY,+10[5]/46,XY[45] LB (7lb0oz) None 
20 47,XY,+10[13]/46,XY[37] SA IUFD 14+ wks 
21 47,XX,+12[26]/46,XX[14]+ LB (8lb4oz) None 
22 47,XY,+13[7]/46,XY[43] LB (5lb2oz) None 
23 47,XY,+15[32]/46,XY[21]+ LB (4lb7oz) PROM, 34+ wks 
24 47,XY,+15[4]/46,XY[26] N/A   
 
25 47,XY,+16+ LB 
pre-eclampsia, IUGR, preterm 33+ 
wks 
26 47,XX,+16[19]/46,XX[2]+ TA   
27 48,XX,+16,+20[16]/46,XX[74] LB (6lb15oz) None 
28 47,XX,+18[9]/46,XX[11] LB (6lb6oz) None 
29 47,XX,+18[10]/46,XX[10] LB Preterm 27+ wks 
30 46,X,+21[17]/47,XX,+21[33]+ TA   
31 47,XX,+22[9]/46,XX[41]+ N/A   
32 45,XX,-22[4]/46,XX[18] LB (7lb3oz) None 
33 45,X/46,XX+ LB (8lb3oz) None 
34 45,X[7]/46,XX[23] LB (6lb11oz) None 
35 45,X[15]/46,XX[5] LB (6lb3oz) None 
36 45,X[2]/46,XX[48]+ SA   
37 45,X[2]/46,XX[48]+ LB (9lb7oz) None 
38 45,X[2]/46,XX[48]+ LB (8lb12oz) None 
39 45,X[10]/46,XX[10] TA  
40 45,X[7]/46,XX[43] SA  
41 45,X[7]/46,XX[43] LB (7lb14oz) None 
42 45,X[5]/46,XY[45] LB (8lb3oz) None  
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Table 5. (continued) 
 
 
43 45,X[9]/46,XY[21] LB (6lb1oz) None 
44 45,X[2]/46,XY[48]+ LB (7lb5oz) None 
45 45,X[2]/46,XY[48]+  LB (7lb2oz) None 
46 45,X[8]/46,XY[12]+ LB (7lb4oz) None 
47 47,XXY[11]/46,XY[39]+ LB  
48 47,XXY[37]/46,XY[13] LB (9lb6oz) fetal cyst and tachycardia 
49 47,XXY[12]/46,XY[18] LB (7lb9oz) None 
50 47,XX,+mar[3]/46,XX[47]+ LB (8lb12oz) None 
51 47,XX,+mar[3]/46,XX[48]+ LB (5lb10oz) None 
52 47,XX,+mar[4]/46,XX[46]+ LB (4lb8oz) None 
53 47,XX,+mar[2]/46,XX[48]+ LB (3lb9oz) chorioamnionitis, preterm 29 wks 
54 47,XX,+mar[4]/46,XX[25]+ LB (7lb5oz) None 
55 47,XY,+mar[2]/46,XY[20]+ LB (8lb2oz) None 
56 47,XX,+mar[2]/46,XX[18]+ LB (6lb6oz) None 
57 47,XX,+mar[3]/46,XX[18]+ LB (7lb3oz) None 
58 47,XY,+mar[8]/46,X,+mar[2]/46,XY[20]+ 
 - marker identified as 17 in origin LB (7lb2oz) None 
59 45,X[13]/46,X,+mar[6]/46,XY[4]+ 
- marker identified as Y in origin LB (7lb4oz) None 
60 47,XY,+mar(mat)[16]/46,XY[4] N/A   
61 47,XY,+mar(mat)[15]/46,XY[5] LB (8lb0oz) None 
62 46,XX/47,XX,+mar TA   
63 47,XY,+mar[8]/46,XY[12] LB (7lb14oz) None 
64 92,XXXX/46,XX[20]+ SA   
65 92,XXXX[13]/46,XX[7] LB (5lb5oz) preterm, 36+ wks 
66 92,XXYY[41]/46,XY[11] LB (7lb7oz) None 
67 46,XX,t(5;7)(p15.1;q34)[4]/46,XX[19]+ LB (8lb5oz) None 
68 46,XX,der(5)t(5;?)(q35.1;?)[2]/46,XX[20]+ LB None 
69 47,XX,+inv dup(8)(p23.1p12)[7] 
/46,XX[43] LB (8lb6oz) None 
70 46,XY,+9,der(13)t(9;13)(q10;q10)[3] 
/46,XY[18] P   
71 47,XX,+i(12p)[5]/46,XX[21]+ LB preterm 22 wks, died at 47 min 
72 46,XX,del(13)(q22)[3]/46,XX[47]+ LB (8lb2oz) None 
73 46,XX,add(13)(p10).ish der(13)(wcp13+) 
[17]/46,XX,der(13;13)(q10;q10),+13[3]+ TA   
74 47,XX,r(15)[6]/46,XX[44]+ LB (8lb4oz) None 
75 47,XY,+inv dup(15)(p10)[18]/46,XY LB (8lb11oz) None 
76 45,X[2]/46,X,i(Xq) TA  
+Previously reported in Thomas, 1998 
N/A – not available; LB – live birth; SA – spontaneous abortion; TA – therapeutic abortion; P – currently pregnant; 
PROM – premature rupture of membranes 
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Pregnancy complications were seen in 11 of 62 (17.7%) CVS patients who did not have a 
spontaneous or therapeutic abortion.  The patient who is currently pregnant was also excluded.  
All of these cases had a follow-up amniocentesis, with the exception of case 6.  Five of the cases 
were previously reviewed in Thomas, 1998.  Case 25 (47,XY,+16) had severe pre-eclampsia and 
IUGR and was delivered by C-section at 33+ weeks.  Case 53 (46,XX/47,XX,+mar) had 
chorioamnionitis and was delivered by C-section at 29+ weeks.  Case 12  (47,XY,+8/46,XY) had 
pre-eclampsia and was delivered vaginally at 39+ weeks.  Case 71 (46,XX/47,XX,+i(12p)) was 
delivered at 22 weeks and the newborn died 47 minutes after birth.  This patient had two 
amniocentesis procedures performed and Thomas (1998) suggested in her paper that the 
premature labor may have been due to multiple invasive procedures.  Lastly, case 23 
(46,XY/47,XY,+15) had PROM and was delivered by C-section at 34+ weeks. 
Five additional cases resulted in preterm delivery.  Case 13 (47,XY,+8/46,XY) had 
PROM and after delayed fetal development, was induced at 21 weeks.  The newborn expired 
soon after birth.  Case 6 (47,XY,+2/46,XY) was delivered by C-section at 36+ weeks.  Of note, 
there was an early loss of a twin.  Case 14 (47,XY,+8/46,XY) was delivered by C-section at 34+ 
weeks. Case 29 (47,XX,+18/46,XX) was delivered by C-section at 27+.  Finally, case 69 
(92,XXXX/46,XX) was delivered at 36+ weeks.   
Other pregnancy complications occurred in one additional case. Case 48 
(47,XXY/46,XY) was complicated by a persistent fetal intraabdominal cyst and fetal 
tachycardia.  
Table 6 includes additional information, including unusual features and anomalies, which 
was recorded about the CVS cases at ultrasound, delivery, and/or follow-up genetic 
consultations.    
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Table 6. Reported Features for Mosaic CVS Cases 
 
Case CVS Results Outcome Reported Features  
1 47,XY,+2[6]/46,XY[42] + LB normal at delivery 
2 47,XY,+2[2]/46,XY[21] + LB   
3 47,XX,+2[4]/46,XX[21] + LB   
4 47,XX,+2[15]/46,XX[5] LB normal at delivery 
5 47,XX,+2[3]/46,XX[47] LB normal at delivery 
6 47,XY,+2[6]/46,XY[14] LB normal at delivery  
7 47,XX,+2[12]/46,XX[18] LB normal at delivery 
8 48,XX,+2,+7[12]/46,XX[38] LB normal at delivery 
9 47,XX,+7[16]/46,XX[4] LB normal at delivery 
10 48,XXX,+7[7]/46,XX[13] LB normal at delivery 
11 47,XX,+7[6]/46,XX[24] LB normal at delivery 
12 47,XY,+8[8]/46,XY[4] + LB   
13 47,XY,+8[2]/46,XY[48] LB neonatal death 
14 47,XY,+8[7]/46,XY[17] LB normal at delivery  
15 47,XY,+9[4]/46,XY[16] + LB   
16 47,XY,+9[18]/46,XY[32] TA   
17 47,XY,+9[3]/46,XY[32] LB normal at delivery 
 
18 47,XY,+10[18]/46,XY[4] + 
LB mild hypotelorism, epicanthal folds, 
single palmar crease- familial 
19 47,XY,+10[5]/46,XY[45] LB normal at delivery 
20 47,XY,+10[13]/46,XY[37] SA   
21 47,XX,+12[26]/46,XX[14] + LB   
22 47,XY,+13[7]/46,XY[43] LB normal at 2 months 
23 47,XY,+15[32]/46,XY[21] + LB   
24 47,XY,+15[4]/46,XY[26] N/A   
25 47,XY,+16+ LB   
26 47,XX,+16[19]/46,XX[2] + TA   
27 48,XX,+16,+20[16]/46,XX[74] LB normal at delivery 
28 47,XX,+18[9]/46,XX[11] LB increased NT, resolved 
29 47,XX,+18[10]/46,XX[10] LB normal at delivery  
30 46,X,+21[17]/47,XX,+21[33] + TA   
31 47,XX,+22[9]/46,XX[41] + N/A   
32 45,XX,-22[4]/46,XX[18] LB normal at delivery 
33 45,X/46,XX+ LB   
34 45,X[7]/46,XX[23] LB normal at delivery 
35 45,X[15]/46,XX[5] LB normal at delivery 
36 45,X[2]/46,XX[48] + SA   
37 45,X[2]/46,XX[48] + LB   
38 45,X[2]/46,XX[48] + LB   
39 45,X[10]/46,XX[10] TA   
40 45,X[7]/46,XX[43] SA  
41 45,X[7]/46,XX[43] LB normal at delivery 
42 45,X[5]/46,XY[45] LB normal at delivery 
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43 45,X[9]/46,XY[21] LB normal at delivery 
44 45,X[2]/46,XY[48] + LB   
45 45,X[2]/46,XY[48] + LB normal at delivery 
46 45,X[8]/46,XY[12] + LB normal at delivery 
47 47,XXY[11]/46,XY[39] + LB   
48 47,XXY[37]/46,XY[13] LB normal at delivery 
49 47,XXY[12]/46,XY[18] LB normal at delivery 
50 47,XX,+mar[3]/46,XX[47] + LB   
51 47,XX,+mar[3]/46,XX[48] + LB   
52 47,XX,+mar[4]/46,XX[46] + LB   
53 47,XX,+mar[2]/46,XX[48] + LB   
54 47,XX,+mar[4]/46,XX[25] + LB   
55 47,XY,+mar[2]/46,XY[20] + LB   
56 47,XX,+mar[2]/46,XX[18] + LB   
57 47,XX,+mar[3]/46,XX[18] + LB increased NT  
58 47,XY,+mar[8]/46,X,+mar[2]/46,XY[20] +  
- marker identified as 17 in origin 
LB 
  
59 45,X[13]/46,X,+mar[6]/46,XY[4] +  
- marker identified as Y in origin 
LB 
  
60 47,XY,+mar(mat)[16]/46,XY[4] N/A   
61 47,XY,+mar(mat)[15]/46,XY[5] LB normal at delivery 
62 46,XX/47,XX,+mar TA   
63 47,XY,+mar[8]/46,XY[12] LB normal at delivery 
64 92,XXXX/46,XX[20] + SA   
65 92,XXXX[13]/46,XX[7] LB normal at delivery 
66 92,XXYY[41]/46,XY[11] LB normal at delivery 
67 46,XX,t(5;7)(p15.1;q34)[4]/46,XX[19] + LB normal at delivery 
68 46,XX,der(5)t(5;?)(q35.1;?)[2]/46,XX[20] + LB   
69 47,XX,+inv dup(8)(p23.1p12)[7] 
/46,XX[43] 
LB 
normal at delivery 
70 46,XY,+9,der(13)t(9;13)(q10;q10)[3] 
/46,XY[18] 
P 
increased NT 
71 47,XX,+i(12p)[5]/46,XX[21] + LB dysmorphic features, Pallister Killian
72 46,XX,del(13)(q22)[3]/46,XX[47] + LB   
73 46,XX,add(13)(p10).ish der(13)(wcp13+) 
[17]/46,XX,der(13;13)(q10;q10),+13[3] + 
TA 
  
74 47,XX,r(15)[6]/46,XX[44] + LB   
75 47,XY,+inv dup(15)(p10)[18]/46,XY LB normal at delivery 
76 45,X[2]/46,X,i(Xq) TA  
+ Previously reported in Thomas, 1998 
NT – nuchal translucency 
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 Unusual features were reported during the newborn period for 5 of the 73 CVS cases 
(6.8%).  Three of these cases (28, 57, 70) showed increased nuchal translucency during 
pregnancy.  One case (10) was reported to have mild hypotelorism, epicanthal folds, and a single 
palmar crease but these characteristics were felt to be familial.  Finally, case 71 was documented 
to have dysmorphic features consistent with Pallister-Killian syndrome.  More information about 
this case is available in Mowery-Rushton et al. (1997). 
Additional cytogenetic testing was performed for the mosaic CVS cases and is included 
in Table 7.  Follow-up amniocentesis was performed for 43 of the 76 cases (56.6%).  Tissue 
analysis was performed for 21 of the 76 mosaic specimens (27.6%) and blood analysis, via cord 
or peripheral blood, was performed for 13 of 76 cases (17.1%).  Overall, 55 of 76 cases (72.4%) 
had some type of follow-up cytogenetic testing.  
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Table 7. Follow-up Testing for Mosaic CVS Cases 
 
 
 
Case CVS Results 
Amniocentesis 
Results Tissue Results Blood Results 
2 47,XY,+2/46,XY+   cord: 46,XY   
4 47,XX,+2/46,XX   amnion, cord, placenta: 46,XX 46,XX 
7 47,XX,+2/46,XX 46,XX     
8 48,XX,+2,+7/46,XX 46,XX     
9 47,XX,+7/46,XX 46,XX     
10 48,XXX,+7/46,XX 46,XX     
11 47,XX,+7/46,XX 46,XX     
 
12 47,XY,+8/46,XY+ 
46,XY.nuc ish  
8cen(D8Z2 x2)     
13 47,XY,+8/46,XY 46,XY skin, placenta: 46,XY 46,XY 
14 47,XY,+8/46,XY 46,XY     
15 47,XY,+9/46,XY+ 46,XY     
 
 
16 47,XY,+9/46,XY 46,XY 
villi 47,XY,+9[2]/46,XY[8], 
skin 46,XY[10], lung 
46,XY[10], liver 46,XY[10]   
17 47,XY,+9/46,XY 46,XY     
18 
47,XY,+10/46,XY+ 46,XY 
villi: 
46,XY[11]/47,XY,+10[19] 46,XY 
21 47,XX,+12/46,XX+ 46,XX     
22 47,XY,+13/46,XY 46,XY     
 
23 47,XY,+15/46,XY+ 
47,XY,+15/ 
46,XY     
24 47,XY,+15/46,XY 46,XY     
 
 
 
25 47,XY,+16+ 46,XY 
cord/mem 46,XY[50]/ plac II 
& IV 47,XY,+16[50]/plac I 
46,XY[39]/47,XY,+16[11]/pla
c III 46,XY[2]/47,XY,+16[48] 46,XY 
 
26 47,XX,+16/46,XX+ 
47,XX,+16[9]/ 
46,XX[7] 
47,XX,+16[95]/46,XX[145]  
multiple tissues   
27 48,XX,+16,+20/46,XX   placenta: 46,XX 46,XX 
28 47,XX,+18/46,XX 46,XX     
29 47,XX,+18/46,XX 46,XX     
30 46,X,+21/47,XX,+21+   46,X,+21/47,XX,+21   
31 47,XX,+22/46,XX+ 46,XX     
32 45,XX,-22/46,XX  villi: 46,XX 46,XX 
33 45,X/46,XX+   45,X/46,XX 46,XX (one cell 45,X) 
34 45,X/46,XX 46,XX     
35 45,X/46,XX 46,XX   
36 45,X/46,XX+   46,XX   
40 
45,X/46,XX  
placenta:  
45,X[2]/46,XX[18]  
 
 
41 45,X/46,XX   
placenta:  
45,X[5]/46,XX[25] 
45,X[1]/ 
46,X,+i(X)(q10)[1]/ 
46,XX[28] 
46 45,X/46,XY+ 46,XY     
 
47 47,XXY/46,XY+ 
47,XXY[5]/ 
46,XY[40] 
placenta:  
47,XXY[14]/46,XY[7] 47,XXY[5]/46,XY[45] 
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48 47,XXY/46,XY 
47,XXY[2]/ 
46,XY[48] 
placenta:  
47,XXY[3]/46,XY[47] 47,XXY[2]/46,XY[48] 
49 47,XXY/46,XY     47,XXY[18]/46,XY[32] 
53 47,XX,+mar/46,XX+ 46,XX     
54 47,XX,+mar/46,XX+ 46,XX     
55 47,XY,+mar/46,XY+ 46,XY     
56 47,XX,+mar/46,XX+ 46,XX     
57 47,XX,+mar/46,XX+ 46,XX     
 
58 47,XY,+mar/46,X,+mar/46,XY+  
- identified as 17 in origin 
47,XY, 
+der(17)[6] 
/46,XY[68]     
 
59 45,X/46,X,+mar/46,XY+  
- identified as Y in origin 
46,X,+mar[5]/ 
46,XY[16].ish 
der(y)(wcpy+)     
62 47,XX,+mar/46,XX   villi, lung: 46,XX   
63 47,XY,+mar/46,XY 46,XY     
64 92,XXXX/46,XX+   46,XX   
66 92,XXYY/46,XY 46,XY     
67 46,XX,t(5;7)(p15.1;q34) 
/46,XX+ 46,XX     
68 46,XX,der(5)t(5;?)(q35.1;?) 
/46,XX+ 46,XX     
69 47,XX,+inv dup(8)(p23.1p12)/ 
46,XX     
47,XX,+inv dup(8) 
(p23.1p12)[18]/46,XX[7]
70 46,XY,+9,der(13)t(9;13) 
(q10;q10)/46,XY 46,XY     
 
71 47,XX,+i(12p)/46,XX+ 
47,XX,+i(12p)/ 
46,XX 47,XX,+i(12p)/46,XX   
72 46,XX,del(13)(q22)/46,XX+ 46,XX villi: 46,XX 46,XX 
73 46,XX,add(13)(p10)/46,XX, 
der(13;13)(q10;q10),+13+   
villi and amnion: 46,XX, 
der(13;13)(q10;q10),+13   
74 47,XX,r(15)/46,XX+ 46,XX     
+ Previously reported in Thomas, 1998 
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Mosaicism was confirmed for 13 of the 55 fetuses (23.6%) which had additional 
cytogenetic testing.  Of these cases, 10 continued their pregnancies and three had complications.  
Case 40 resulted in a spontaneous abortion 15 days after the CVS procedure.  As previously 
mentioned, one case (71) considered to have Pallister-Killian syndrome delivered at 22 weeks 
and resulted in a neonatal death.  In addition, case 23 resulted in a preterm delivery at 34 weeks. 
In some cases that involved a marker chromosome or structural aberration, the parents 
had blood analysis to determine if the chromosome abnormality was inherited or de novo.  The 
results from this testing are listed in Table 8. 
 
Table 8. Parental Blood Analysis for Mosaic CVS Cases 
 
Case CVS Results Maternal Karyotype Paternal Karyotype 
51 47,XX,+mar[3]/46,XX[48] + 46,XX 47,XY,+mar/46,XY
52 47,XX,+mar[4]/46,XX[46] + 46,XX 46,XY 
53 47,XX,+mar[2]/46,XX[48] + 46,XX 46,XY 
54 47,XX,+mar[4]/46,XX[25] + 46,XX 47,XY 
56 47,XX,+mar[2]/46,XX[18] + 46,XX   
58 47,XY,+mar[8]/46,X,+mar[2]/46,XY[20] + 46,XX 46,XY 
60 47,XY,+mar(mat)[16]/46,XY 47,XX,+mar/46,XX   
61 47,XY,+mar(mat)[15]/46,XY 
47,XX,+mar1[8] 
/47,XX,+mar2[2]  
/46,X,+mar1[2]/46,XX[8]   
62 46,XX/47,XX,+mar 46,XX   
63 47,XY,+mar[8]/46,XY[12] 46,XX 46,XY 
67 46,XX,t(5;7)9p15.1;q34)[4]/46,XX[19] + 46,XX 46,XY 
69 47,XX,+inv dup(8)(p23.1p12)[7]/46,XX[43] 46,XX 46,XY 
70 
46,XY,+9,der(13)t(9;13)(q10;q10)[3] 
/46,XY[18] 46,XX 46,XY 
73 
46,XX,add(13)(p10).ish 
der(13)(wcp13+)[17] 
/46,XX,der(13;13)9q10;q10),+13[3] + 46,XX 46,XY 
75 47,XY,+inv dup(15)(p10)[18]/46,XY 46,XX 46,XY 
+ Previously reported in Thomas, 1998 
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 Of the 23 cases involving a marker chromosome or structural aberration, 15 (65.2%) had 
parental blood analysis.   Three of these cases identified a marker in one of the parents’ 
karyotypes.  Parental karyotypes were normal in all of the structural aberration cases. 
4.3 MOSAIC AMNIOCENTESIS CASES 
Pregnancy outcome information was obtained for 43 of the 59 mosaic amniocentesis cases 
(72.9%).  These outcomes are listed in Table 9.  Although cases referred for mosaic CVS were 
not included in the above calculation, the amniocentesis outcomes are included in the table.  Of 
the patients with available pregnancy outcomes, one had a spontaneous abortion (1.7%) and 
eight had a therapeutic abortion (13.6%).  The therapeutic abortions were performed because of 
the following abnormal results: 47,XX,+9/46,XX; 47,XY,+18/46,XX; 47,XX,+21/46,XX; 
45,X/46,XX; 45,X/46,XY; 46,XX,+mar/46,XX; 47,XY,+i(12)(p10)/46,XY; and 
46,XY,der(13)t(13;?)/46,XY.  Two cases (both 45,X/46,XX) had not delivered as of March 25, 
2006. 
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Table 9. Pregnancy Complications for Mosaic Amniocentesis Results 
 
Case Amniocentesis Results Outcome Pregnancy complications 
77 47,XX,+2[8]/46,XX[42] + N/A   
78 47,XX,+8[5]/46,XX[25] LB (8lb0oz) None 
79 47,XX,+9[9]/46,XX[13] TA   
80 47,XX,+12[2]/46,XX[48] + N/A   
81 47,XX,+13[3]/46,XX[62] LB  
82 47,XY,+15/46,XY*+ LB (4lb7oz) PROM 34 wks 
83 47,XX,+16[19]/46,XX[7]* + TA   
84 47,XY,+18[46]/46,XY[4] + TA   
85 47,XX,+18[18]/46,XX[2] N/A   
86 47,XX,+20[5]/46,XX[45] + LB (7lb14oz) None 
87 47,XX,+20[6]/46,XX[11] + LB (4lb14oz) ? r/o IUGR 
88 47,XY,+20[7]/46,XX[41] + N/A   
89 47,XX,+21[36]/46,XX[9] + LB (8lb3oz) None 
90 47,XX,+21[35]/46,XX[14] + TA   
91 47,XX,+21[4]/46,XX[34] + LB None 
92 47,XX,+21[4]/46,XX[40] + LB (7lb7oz) None 
93 47,XX,+21[9]/46,XX[37] TA   
94 47,XY,+21[23]/46,XY[4] LB (8lb1oz) None 
95 45,XY,-21[4]/46,XY[30] N/A   
96 45,X[9]/46,XX[36] + N/A   
97 45,X[48]/46,XX[2] + SA 20 wk fetal demise 
98 45,X[15]/46,XX[35] + N/A   
99 45,X[5]/46,XX[25] + N/A   
100 45,X[7]/46,XX[8] + LB (8lb5oz) None 
101 45,X[5]/46,XX[10] P  
102 45,X[6]/46,XX[19] P   
103 45,X[3]/46,XX[17] + LB (7lb6oz) None 
104 45,X[33]/46,XX[17] + N/A   
105 45,X[10]/46,XX[16] LB (8lb10oz) None 
106 45,X[4]/46,XX[16] LB (6lb4oz) None 
107 45,X[10]/46,XX[32] LB (8lb0oz) None 
108 45,X[8]/46,XX[8] LB (6lb0oz) None 
109 45,X[5]/46,XX[10] TA   
110 45,X[5]/46,XX[27] LB  
111 45,X[22]/46,XX[3] N/A   
112 45,X[39]/46,XX[7] LB  
113 45,X[10]/46,XX[5] LB (6lb15oz) induced - hypertension 
114 45,X[5]/46,XY[25] TA   
115 45,X[3]/46,XY[22] LB (7lb11oz) None 
116 45,X[15]/46,XY[35] LB (6lb14oz) None 
117 45,X[2]/46,XY[18] + N/A   
118 45,X[3]/46,XY[41] + LB   
119 47,XXX[5]/45,X[3]/46,XX[22] LB (6lb4oz) None 
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120 47,XXY[13]/45,X[12] + LB (5lb2oz) None 
121 47,XXY/46,XY+ LB (7lb8oz) None 
122 47,XXY[5]/46,XY[40]* + LB  
123 47,XXY[2]/46,XY[48]* LB (9lb6oz) fetal cyst, tachycardia 
124 47,XXY[5]/46,XY[20] LB (8lb5oz) None 
125 47,XXY[6]/46,XY[34] N/A  
 
126 47,XYY[8]/46,XY[8] 
LB (6lb10oz, 
7lb0oz) preterm 35+ wks  
127 47,XX,+mar[5]/46,XX[40].ish  
der(22)(D14Z1/D22Z1+,wcp22+) N/A   
128 47,XX,+mar[44]/46,XX[6] 
-identified as 6 in origin LB (5lb8oz) None 
129 47,XX,+mar[6]/46,XX[9] 
-identified as 7 in origin TA ruptured membranes 
130 47,XX,+mar[10]/46,XX[5].ish  
inv dup(13)(p10) LB (7lb9oz) None 
131 47,XY,+mar[6]/46,XY[28].ish  
dup(21)(q11.2) N/A   
132 45,X[27]/47,X,inv(Y)(p11q12),+mar[5] 
/46,XY[13] + LB (6lb14oz) None 
133 46,X,+mar[5]/46,XY[16].ish  
der(y)(wcp+)*+ LB (7lb4oz) None 
134 46,XY,der(5)del(5)(p14.2)dup(5)(q14q22) 
t(5;14)(q13;q32)[9]/46,XY[31] N/A   
135 47,XX,+i(12p)[1]/46,XX[62]* + LB preterm delivery 22 wks, died 47 mins
136 47,XY,+i(12)(p10)[10]/46,XY[5] TA   
137 46,XY,der(13)t(13;?)[5]/46,XY[44] + TA   
138 47,XY,+der(17)[6]/46,XY[68]* + LB (7lb2oz) None 
139 46,X,i(Xq)[6]/46,XX[90] + N/A   
140 46,X,idic(Y)(q11.2)[9]/45,X[6] LB (6lb0oz) None 
141 45,X[37]/46,X,psu idic (Y)(p11.32)[4] LB (3lb11oz) preterm 32 wks 
142 45,X[9]/46,X,i(Y)(p10)[6] LB (8lb8oz) None 
*Mosaicism was also seen on CVS specimen 
+Previously reported in Thomas, 1998 
N/A – not available; LB – live birth; SA – spontaneous abortion; TA – therapeutic abortion; P – currently pregnant; 
PROM – premature rupture of membranes 
 
 
 
 
 
 36 
 Pregnancy complications were seen for 4 of 43 amniocentesis patients (9.3%).  Cases that 
were excluded include patients who were referred because of a mosaic CVS result and those who 
had a spontaneous or therapeutic abortion.  Two of these cases had preterm deliveries.  Case 126 
(47,XYY/46,XX) was delivered vaginally at 35+ weeks and case 141 (45,X/46,X,psu 
idic(Y)(p11.32)) was delivered vaginally at 32 weeks . 
In addition, case 113 (45,X/46,XX) was induced due to hypertension, which may indicate 
that the beginnings of pre-eclampsia were present. Case 87 (47,XX,+21/46,XX) was 4 lbs. 14 oz. 
at birth, which might indicate that IUGR was present.  It should also be mentioned that case 129 
(47,XX,+mar/46,XX) was complicated by ruptured membranes but was electively terminated. 
Table 10 includes additional information, including unusual features and anomalies, 
which was recorded about the amniocentesis cases at ultrasound, delivery, and/or follow-up 
genetic consultations.    
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Table 10. Reported Features for Mosaic Amniocentesis Cases 
 
Case Amniocentesis Results Outcome Reported Features 
77 47,XX,+2[8]/46,XX[42] + N/A   
 
 
 
78 47,XX,+8[5]/46,XX[25] 
LB increased NT, mild ventriculomegaly, mild  
hydronephrosis (resolved), prominent pillars of 
philtrum, full lower lip, extra crease on both 
earlobes, tall stature, normal dev at 5 mos 
79 47,XX,+9[9]/46,XX[13] TA Dandy Walker formation 
80 47,XX,+12[2]/46,XX[48] + N/A   
81 47,XX,+13[3]/46,XX[62] LB   
82 47,XY,+15/46,XY*+ LB   
83 47,XX,+16[19]/46,XX[7]* + TA   
84 47,XY,+18[46]/46,XY[4] + TA choroid plexus cysts 
85 47,XX,+18[18]/46,XX[2] N/A cystic hygroma 
86 47,XX,+20[5]/46,XX[45] + LB   
87 47,XX,+20[6]/46,XX[11] + LB   
88 47,XY,+20[7]/46,XX[41] + N/A short limbs, duodenal atresia 
89 47,XX,+21[36]/46,XX[9] + LB Down syndrome 
90 47,XX,+21[35]/46,XX[14] + TA pathology report noted Simian crease 
91 47,XX,+21[4]/46,XX[34] + LB no clinical features of Down syndrome 
92 
47,XX,+21[4]/46,XX[40] + 
LB distal axial triradii only feature of Down 
syndrome 
93 47,XX,+21[9]/46,XX[37] TA   
94 47,XY,+21[23]/46,XY[4] LB increased NT 
95 45,XY,-21[4]/46,XY[30] N/A   
96 45,X[9]/46,XX[36] + N/A   
97 45,X[48]/46,XX[2] + SA cystic hygroma 
98 45,X[15]/46,XX[35] + N/A   
99 45,X[5]/46,XX[25] + N/A   
100 45,X[7]/46,XX[8] + LB coarctation of the aorta 
101 45,X[5]/46,XX[10] P   
102 45,X[6]/46,XX[19] P   
103 45,X[3]/46,XX[17] + LB   
104 45,X[33]/46,XX[17] + N/A   
105 
45,X[10]/46,XX[16] 
LB normal at delivery,  
no features of Turner at 5 months 
106 
45,X[4]/46,XX[16] 
LB normal at delivery,  
no features of Turner at 4.5 months 
107 45,X[10]/46,XX[32] LB normal u/s and echo 
 
108 45,X[8]/46,XX[8] 
LB diaphragmatic hernia, mild edema,  
hyperconvex nails, posteriorly rotated ears 
109 45,X[5]/46,XX[10] TA   
110 45,X[5]/46,XX[27] LB normal echo, no features of Turner 
111 45,X[22]/46,XX[3] N/A   
112 45,X[39]/46,XX[7] LB normal appearance and development at 9 mos 
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113 45,X[10]/46,XX[5] LB normal at delivery 
114 45,X[5]/46,XY[25] TA   
 
115 45,X[3]/46,XY[22] 
LB choroid plexus cysts,  
normal male genitalia on u/s 
116 45,X[15]/46,XY[35] LB normal appearance and development 11.5 mos 
117 45,X[2]/46,XY[18] + N/A   
118 45,X[3]/46,XY[41] + LB   
119 47,XXX[5]/45,X[3]/46,XX[22] LB   
120 47,XXY[13]/45,X[12] + LB   
121 47,XXY/46,XY+ LB   
122 47,XXY[5]/46,XY[40]* + LB   
123 47,XXY[2]/46,XY[48]* LB normal at delivery  
124 47,XXY[5]/46,XY[20] LB normal at delivery 
125 47,XXY[6]/46,XY[34] N/A  
 
126 47,XYY[8]/46,XY[8] 
LB one twin mosaic, did not want to know which 
one, both appeared normal 
127 47,XX,+mar[5]/46,XX[40].ish  
der(22)(D14Z1/D22Z1+,wcp22+) 
N/A 
  
128 47,XX,+mar[44]/46,XX[6] 
-identified as 6 in origin 
LB 
normal appearance and development at 15 mos 
129 47,XX,+mar[6]/46,XX[9] 
-identified as 7 in origin 
TA pump twin – hypoplastic left heart, left lung 
aplasia, acardiac twin - amorphous 
130 47,XX,+mar[10]/46,XX[5]  
(inv dup(13)(p10)) 
LB 
normal at delivery 
131 47,XY,+mar[6]/46,XY[28].ish  
dup(21)(q11.2) 
N/A 
  
132 45,X[27]/47,X,inv(Y)(p11q12),+mar[5]
/46,XY[13] + 
LB mild edema of hands and feet,  
hyperconvex nails 
133 46,X,+mar[5]/46,XY[16].ish  
der(y)(wcp+)*+ 
N/A 
  
134 46,XY,der(5)del(5)(p14.2)dup(5) 
(q14q22)t(5;14)(q13;q32)[9]/46,XY[31]
N/A 
  
135 47,XX,+i(12p)[1]/46,XX[62]* + LB dysmorphic features - Pallister Killian  
 
136 47,XY,+i(12)(p10)[10]/46,XY[5] 
TA 
diaphragmatic hernia, Pallister -Killian 
137 46,XY,der(13)t(13;?)[5]/46,XY[44] + TA   
138 47,XY,+der(17)[6]/46,XY[68]* + LB   
139 46,X,i(Xq)[6]/46,XX[90] + N/A   
140 46,X,idic(Y)(q11.2)[9]/45,X[6] LB normal at delivery and at 4.5 years  
 
141 45,X[37]/46,X,psu idic (Y)(p11.32)[4] 
LB umbilical hernia, hyperconvex nails, 
hypogonadism, last seen at 3 mos 
142 45,X[9]/46,X,i(Y)(p10)[6] LB increased NT 
*Mosaicism was also seen on CVS specimen 
+Previously reported in Thomas, 1998 
NT – nuchal translucency; u/s - ultrasound 
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 Of the 59 amniocentesis patients, 18 (30.5%) were reported to have some unusual 
features and anomalies.  Five of these cases were electively terminated.  Case 79 
(47,XX,+9/46,XX) was found to have a Dandy Walker formation on ultrasound, and case 90  
(46,XX/47,XX,+21) was noted to have a Simian crease by pathology report.  Case 84 
(47,XY,+18/46,XY) was found to have choroid plexus cysts on ultrasound.  Case 129 
(47,XX,+mar/46,XX) involved monochorionic twins and abnormalities were reported for both.  
Ultrasound showed that the “pump twin” had a hypoplastic left heart and left lung aplasia while 
the second, “acardiac twin,” was amorphous.  Finally, case 136 (47,XY,+i(12)(p10)/46,XY) was 
documented to have a diaphragmatic hernia on ultrasound and was considered to have Pallister-
Killian syndrome. 
Three cases with results that were mosaic for trisomy 21 had some features of Down 
syndrome.  Case 89 was reported to have Down syndrome but no specific features were 
indicated.  Case 92 was reported to have distal axial triradii, but that was the only feature of 
Down syndrome.  Case 94 was reported to have increased nuchal translucency on ultrasound. 
Four cases with results that were mosaic for monosomy X were reported to have 
anomalies.  Case 97 (45,X/46,XX) was reported to have cystic hygroma by ultrasound.  Case 100 
(45,X/46,XX) was reported to have coarctation of the aorta.  Case 108, (also 45,X/46,XX) was 
reported to have a diaphragmatic hernia, mild edema, and hyperconvex nails.  The facial features 
were normal except for posteriorly rotated ears.  Case 115 (45,X/46,XY) was documented to 
have choroid plexus cysts on ultrasound, but genitalia appeared normal.  
Three other cases involving mosaic trisomies were reported to have anomalies.  Case 78 
(47,XX,+8/46,XX) was noted by ultrasound to have an increased nuchal translucency, mild 
ventriculomegaly, and mild hydronephrosis.  The hydronephrosis resolved during pregnancy.  
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The infant was reported to have prominent pillars of philtrum, a full lower lip, an extra crease on 
both earlobes, and tall stature at five months of age, but she was found to be developing 
normally.  Case 85 (47,XX,+18/46,XX) had cystic hygroma, which was identified by ultrasound 
and case 88 (47,XX,+21/46,XX) had short limbs and duodenal atresia, which were identified by 
ultrasound. 
Lastly, three cases involving structural aberrations of the sex chromosomes were reported 
to have unusual features.  Case 132 (45,X/47,X,inv(Y)(p11q12),+mar/46,XY) was reported to 
have mild edema of the hands and feet and hyperconvex nails. Case 141 (45,X/46,X,psu idic 
(Y)(p11.32)) was reported to have an umbilical hernia, hyperconvex nails, and hypogonadism.  
Finally, case 142 (45,X/46,X,i(Y)(p10)) was reported to have an increased nuchal translucency 
by ultrasound. 
Follow-up cytogenetic testing was performed for 28 of 59 (47.5%) mosaic amniocentesis 
cases.  These test results are listed in Table 11.  A total of 17 of the 28 cases were confirmed as 
true mosaics (60.7%).  Sixteen of the mosaic amniocentesis specimens (27.1%) had tissue 
follow-up performed.  Of these, three did not grow, including a mosaic trisomy 18 case (84), a 
mosaic trisomy 21 case (91), and a mosaic monosomy X case (107).  Seven of the tissues 
confirmed true fetal mosaicism (79, 90, 93, 118, 126,129, and 136) while three others indicated 
non-mosaic Turner syndrome.  In addition, 18 mosaic amniocentesis cases (30.5%) had blood 
analysis.  Of these, 13 confirmed true mosaicism, nine of which did not have tissue analysis.  
These cases include 78, 92, 107, 108, 110, 116, 124, 128, and 141.  Case 132 
(45,X/47,X,inv(Y)(p1.2q12),+mar/ 46,XY) was confirmed mosaicism by blood analysis while 
tissue analysis indicated non-mosaic Turner.   
 
 41 
Table 11. Follow-up Testing for Mosaic Amniocentesis Results 
 
Case Amniocentesis Results Tissue Results Blood Results 
77 47,XX,+2/46,XX+  46,XX 
78 47,XX,+8/46,XX  47,XX,+8[11]/46,XX[19] 
 
79 47,XX,+9/46,XX 
lung, heart, brain, liver: 
47,XX,+9[10]/46,XX[30]  
81 47,XX,+13/46,XX  46,XX 
84 47,XY,+18/46,XY+ no growth  
90 47,XX,+21/46,XX+ 47,XX,+21[32]/46,XX[18]  
91 47,XX,+21/46,XX+ no growth 46,XX 
92 47,XX,+21/46,XX+  47,XX,+21[13]/46,XX[37] 
 
93 47,XX,+21/46,XX 
villi, kidney, lung: 
47,XX,+21[11]/46,XX[29]  
96 45,X/46,XX+ 46,XX  
97 45,X/46,XX+ 45,X  
106 45,X/46,XX  46,XX 
107 45,X/46,XX villi: no growth 45,X[8]/46,XX[22] 
108 45,X/46,XX  45,X[10]/46,XX[20] 
110 45,X/46,XX  45,X[2]/46,XX[48] 
112 45,X/46,XX villi: 45,X  
114 45,X/46,XY chorionic villi 45,X, lung 46,XY  
115 45,X/46,XY  46,XY 
116 45,X/46,XY  45,X[3]/46,XY[56] 
118 45,X/46,XY+ 45,X[30]/46,XY[21] 45,X[1]/46,XY[49] 
124 47,XXY/46,XY  47,XXY[6]/46,XY[15] 
126 47,XYY/46,XY villi: 47,XYY[7]/46,XY[3] 47,XYY[4]/46,XY[7] 
 
128 47,XX,+mar/46,XX  
47,XX,+mar[17]/46,XX[3].ish 
der(6)(D6Z1+,WCP6-) 
 
 
129 47,XX,+mar/46,XX 
twin A: 
47,XX,+mar[20]/46,XX[20], 
twin B: no growth 
47,XX,+mar[8]/46,XX[12].ish 
der(7)(wcp7+,7ptel-,D7Z1-, 
7qtel-,ELN-,7p paint+) 
132 45,X/47,X,inv(Y)(p11q12),
+mar/46,XY+ 45,X 
45,X[9]/47,X,inv(Y)(p1.2q12),+
mar[7]/46,XY[4] 
 
136 
47,XY,+i(12)(p10)/46,XY 
villi: 47,XY,+i(12p)(p10)[11] 
/46, XY[14], 
lung: 47,XY,+i(12p)(p10)[13] 
/46,XY[12]  
137 46,XY,der(13)t(13;?) 
/46,XY+ 46,XY (one cell 45,X)  
141 45,X/46,X,psu 
idic (Y)(p11.32)  
45,X[4]/46,X,psu 
idic(Y)(p11.32)[16] 
+Previously reported in Thomas, 1998 
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In some cases that involved a marker chromosome or structural aberration, the parents 
had blood analysis to determine if the chromosome abnormality was inherited or de novo.  The 
results from this testing are listed in Table 12. 
 
Table 12. Parental Blood Analysis for Mosaic Amniocentesis Cases 
 
Case Amniocentesis Results 
Maternal 
Karyotype 
Paternal 
Karyotype 
127 47,XX,+mar[5]/46,XX[40].ish der(22) 46,XX 46,XY 
128 
47,XX,+mar[44]/46,XX[6] 
 -identified as  6 in origin 46,XX 46,XY 
130 47,XX,+mar[10]/46,XX[5].ish inv dup(13)(p10) 46,XX 46,XY 
131 47,XY,+mar[6]/46,XY[28].ish dup(21)(q11.2) 46,XX 46,XY 
141 46,X,idic(Y)(q11.2)[9]/45,X[6] 46,XX 47,XYY 
 
 Of the 11 cases involving a marker chromosome or structural aberration, 5 (45.5%) had 
parental blood analysis.  Four of these cases had normal results, but in case 141, the father had a 
47,XYY karyotype. 
4.4 UPD TESTING 
UPD testing was also performed for 7 mosaic CVS patients (9.2%).  These cases are listed in 
Table 13.  All of the cases resulted in biparental inheritance. 
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Table 13. UPD Test Results 
 
Case CVS Result Amnio Result UPD Result 
8 46,XX/48,XX,+2,+7 46,XX biparental 
9 46,XX/47,XX,+7 46,XX biparental 
11 46,XX/47,XX,+7 46,XX biparental 
22 46,XY/47,XY,+13 46,XY biparental 
23 46,XY/47,XY,+15 46,XY/47,XY,+15biparental 
24 46,XY/47,XY,+15 46,XY biparental 
25 47,XY,+16 46,XY biparental 
 
The frequency of each chromosome involved in UPD testing is indicated in Figure 3.  Of note, a 
case with a 48,XX,+2,+7 CVS result was only tested for biparental inheritance of chromosome 7 
(not chromosome 2). 
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Figure 3. Frequency of UPD Testing by Chromosome 
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5.0  DISCUSSION 
5.1 RATE OF MOSAICISM 
To determine if the data from this study compared with literature, previous studies were 
reviewed.  Thomas (1998) included many of these reports in her study, including information 
from Phillips et al. (1996), who reviewed thirteen studies on placental mosaicism detected by 
CVS.  This information is contained in Table 14. Recent studies by Grati et al. (2006) and Stetten 
et al. (2004) were added to this information.  Articles marked with the designation a, b, etc. 
indicate that the corresponding papers could contain some overlapping data.  Of note, study 3 
contains patients from studies 4a, 4b, 7a, 7b, 8, and 9. 
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Table 14. Review of Past Studies of CVS Mosaicism 
 
# Study-Author and Year direct cultured # of cases # of 
mosaics 
% 
mosaicism 
1a Canadian Collaborative (1989) yes yes 947 19 2.00% 
1b *Teshima et al. (1992) yes yes 1,040 18 1.80% 
2a *Vejerslev and Mikkelsen (1989) yes yes 11,855 141 1.20% 
2b *Medical Research Party (1991) yes yes 1,102 18 1.63% 
2c Hahnemann and Vejerslev (1997) yes yes 92,246 1,415 1.50% 
3 *Ledbetter et al. (1992) yes yes 11,436 108 0.94% 
4a Wapner, et al. (1992) yes yes 11,043 289 2.60% 
4b Johnson et al. (1990) yes yes 4,319 55 1.30% 
5a *ACC Collaborative (1994) yes yes 7,595 88 1.20% 
5b *Wolstenholme et al. (1994) yes yes 11,755 CPM 73 0.62% 
6 *Wang et al. (1993) yes yes 2,612 56 2.10% 
7a Goldberg and Wohlferd (1997) no yes 11,200 140 1.30% 
7b *Hogge et al. (1986) no yes 1,000 12 1.70% 
8 *Fryburg et al. (1993) no yes 1,724 20 1.16% 
9 *Roland et al. (1994) yes yes 3,258 CPM 26 0.83% 
10 *Smidt-Jensen et al. (1993) yes yes 2,928 30 1.02% 
11 *Miny et al. (1991) yes yes 2,290 29 1.27% 
12 *Callen et al. (1991) yes yes 1,312 20 1.52% 
13 Breed et al. (1991) yes yes 2,103 26 1.20% 
14 Phillips et al. (1996) yes yes 59,937 637 1.06% 
15 Stetten et al. (2004) yes yes 4,000 38 0.95% 
16 Grati et al. (2006) yes  yes 15,109 273 1.81% 
17 Magee-Womens Hospital  
(1991-2005) 
no yes 4,599 76 1.65% 
*Studies reviewed by Phillips et al. (1996) 
 
 
The percentage of mosaicism observed in the above CVS studies ranged from 0.62% 
(Wolstenholme et al., 1994) to 2.6% (Wapner et al., 1992).  The mosaicism rate observed at 
Magee-Womens Hospital between the years of 1991 and 2005 was 1.65%.  This number falls 
within the rate of mosaicism observed in literature. 
Thomas (1998) also reviewed previous papers that observed mosaicism in amniocentesis 
samples.  The data from these papers are listed in Table 15 along with the data from this study.  
As with Table 11, the a, b, and c designations refer to papers that could contain some 
overlapping data.  
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Table 15. Review of Past Studies of Amniocentesis Mosaicism 
 
# Study – Author and Year # of amnios # of level III 
mosaics 
% mosaicism 
1a Worton and Stern (1984) 12,386 34 0.30%
1b Canadian Collaborative (1989) 933 1 0.11%
1c Teshima et al. (1992) 968 1 0.10%
2 Hsu et al. (1996) 179,663 555 0.30%
3 Smidt-Jensen et al. (1993) 1,075 1 0.10%
4 Magee-Womens Hospital (1991-2005) 15,688 59 0.38%
 
 
The percentage of mosaicism in the five articles reviewed ranged from 0.10% (Teshima 
et al., 1992; Smidt-Jensen et al., 1993) to 0.30% (Worton and Stern, 1984; Hsu et al., 1996).  The 
rate of amniocentesis mosaicism observed in this study, excluding those referred for CVS 
mosaicism, was 0.38%.  This rate is slightly higher than those observed in literature.  However, it 
is closer to the rates associated with the larger studies (Worton and Stern, 1984; Hsu et al., 
1996).   
Fetal mosaicism in this study was seen in 23.6% of the CVS specimens that had follow-
up cytogenetic testing and in 60.7% of amniocentesis specimens with follow-up.  Previous 
studies have reported that fetal mosaicism is confirmed in approximately 10-20% of mosaic CVS 
cases and about 40% of amniocentesis cases (Smidt-Jensen, et al, 1993; Stetten et al., 2004; 
Hahnemann and Vejerslev, 1997; Smith et al., 1999).  These studies looked at mosaicism 
detected by both direct and cultured CVS preparations.  In addition, Ledbetter et al. (1992) 
studied mosaicism detected by only cultured CVS preparations and reported a 25% fetal 
mosaicism rate.  Also, Hsu et al. (1997) reported that true mosaicism involving an autosome 
accounts for 44-47% of all mosaic cases detected in amiotic fluid.  In our study, 55.6% of mosaic 
autosomal amniocentesis cases that had follow-up testing were found to be true mosaics.  The 
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rates of fetal mosaicism in this study fall within the range of true fetal mosaicism detected by 
CVS reported in literature but are slightly higher than the reported rate detected by 
amniocentesis. 
5.2 KARYOTYPE/PHENOTYPE CORRELATIONS 
This study found mosaic results involving trisomy for chromosomes 2, 7, 8, 9, 10, 12, 13, 15, 16, 
18, 20, 21, 22, X, and Y.  In addition, there was monosomy for chromosomes 21, 22, and X, 
tetraploidy, structural aberrations, and supernumerary marker chromosomes.  The percentage of 
each category of chromosome abnormality identified in CVS mosaic cases is listed in Table 16 
and compared to the results reported by Phillips et al. (1996).   
 
Table 16. Types of Chromosome Abnormalities Identified in Mosaic CVS Cases 
 
Type of Mosaicism Phillips et al. (1996) Magee-Womens Hospital 
Uncommon autosomal trisomies 40.1% 35.5%
Common autosomal trisomies (13, 18, 21) 16.8% 5.3%
Sex chromosome aneuploids 23.2% 22.4%
Marker chromosomes 6.4% 18.4%
Structural aberrations 7.5% 13.2%
Polyploidy 6.0% 3.9%
Monosomy 1.3%
 
 When comparing our study to Phillips et a. (1996), there was a higher percentage of 
marker chromosomes and structural aberrations and a lower percentage of common trisomies.  In 
studies by Grati et al. (2006) and Hahnemann and Vejerslev (1997), the most common of the 
autosomal trisomies included 2, 7, 13, 18, and 21.  However, the most common autosomal 
trisomies in our study included 2, 7, 8, 9, 10, and 16.   
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Table 17 lists the percentage of each category of chromosome abnormality identified in 
amniocentesis mosaic cases and compares them to the results reported by Hsu et al. (1996). 
 
Table 17. Types of Chromosome Abnormalities Identified in Mosaic Amniocentesis Cases 
 
Type of Mosaicism Hsu et al. (1996) Magee-Womens Hospital 
Autosomal numerical 26.5% 28.8% 
Autosomal structural 10.3% 7.6% 
Sex chromosome numerical 42.7% 47.0% 
Sex chromosome structural 5.0% 6.1% 
Marker 15.3% 10.6% 
 
 It has been estimated from previous studies that approximately 70% of mosaic autosomal 
trisomy cases detected in amniotic fluid involve chromosomes 13, 18, 20, and 21 (Wallerstein et 
al., 2000).  The most common autosomal trisomies in our study were 18, 20, and 21, which is to 
be expected based on results from literature. 
5.2.1 Trisomy 2 
Complete trisomy 2 results in first trimester pregnancy loss and can only be compatible with life 
in a mosaic state that is predominantly confined to the placenta.  Pregnancy outcome can range 
from normal to neonatal death and oligohydramnios and poor intrauterine growth are the most 
common features (Robinson, 2001). In most cases where trisomy is found by CVS but not by 
amniocentesis, the outcome is normal, but an abnormal outcome can occur.  Shaffer et al. (1996) 
reported nine cases of confined placental mosaicism for trisomy 2.  Of these cases, six had 
normal outcomes, two had intrauterine growth retardation (IUGR), and one was terminated and 
no outcome data was available. Although most of these cases had normal outcomes, Shaffer et al. 
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(1996) speculated that CPM for trisomy 2 may increase risk for IUGR.  Trisomy 2 that is 
confined to the placenta is usually of mitotic origin, which explains the generally good outcome.  
Cases that have been associated with poor outcome were usually associated with maternal 
meiotic origin of trisomy (Wolstenholme, 1996).  
Our study identified eight cases of trisomy 2 mosaicism by CVS.  One of these cases (8) 
also showed trisomy 7 mosaicism.  Of these cases, four (2, 4, 7, 8) were confirmed as confined to 
the placenta by follow-up testing while the other four (1, 3, 5, 6) had no further testing performed 
Case 6 was delivered by C-section at 36 weeks.  This case also involved the spontaneous loss of 
a twin.  Although one of the eight cases had pregnancy complications, none of the cases were 
noted to have IUGR or any other abnormalities.  Also, it is possible that the presence of a second 
aneuploidy increased the risk for a pregnancy complication. 
Abnormal outcome is more likely to occur when there are high levels of trisomy in the 
term placenta and there is a of low level trisomy in the fetus (Robinson, 2001).  When trisomy 2 
mosaicism is diagnosed by amniocentesis, the risk of poor outcome is much higher.  A study by 
Hsu et al. (1997) suggested that an increased risk is associated with trisomy 2 mosaicism 
detected by amniocentesis.  They identified 11 cases of trisomy 2 mosaicism detected in 
amniotic fluid.  Of these cases, one resulted in a normal live birth, one resulted in a live birth 
with IUGR, four resulted in a live birth with IUGR and multiple anomalies, three resulted in 
stillbirths or intrauterine deaths, and two resulted in elective terminations due to abnormal 
findings.  The one normal outcome had only four percent trisomy 2 cells in the amniocytes.   
Our study identified one case of trisomy 2 mosaicism detected by amniocentesis.  Blood 
analysis indicated a normal karyotype, but no pregnancy outcome information was available.  
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Information pertaining to the pregnancy would have been useful but accurate conclusions could 
not have been drawn based on one case.  
To date, six cases of maternal UPD2 have been reported.  Four of these cases have been 
associated with IUGR and varying abnormalities associated with oligohydramnios, but these 
outcomes are most likely explained by cryptic fetal mosaicism.  The other two cases were found 
in healthy females.  Based on these cases, it is unlikely that there is an imprinting effect 
associated with maternal UPD2.  No cases of paternal UPD2 have been reported (Robinson, 
2001).  UPD2 testing was not performed for any of the cases identified in this study. 
5.2.2 Trisomy 7 
Complete trisomy 7 is not compatible with life, but it is one of the most common aneuploidies 
detected on CVS.  As an example, Sachs et al. (1990) reported five cases of trisomy 7 mosaicism 
detected by CVS, and all five of these cases resulted in normal outcomes.  Trisomy 7 that is 
confined to the placenta usually results from the somatic duplication of chromosome 7.  The 
mitotic origin indicates a generally good outcome and a low risk for fetal UPD (Wolstenholme, 
1996).  Kalousek et al., (1996) reported 14 pregnancies with trisomy 7 mosaicism, which were 
identified by CVS.  All of these cases were confirmed as CPM, and UPD7 was only present in 
one case, illustrating the relatively low occurrence of UPD7 associated with CPM.   
Our study identified four cases of trisomy 7 mosaicism by CVS.  One of these cases also 
involved trisomy 2 mosaicism, and another case also involved mosaicism for trisomy X.  All 
four of these cases were confirmed as CPM by amniocentesis.  None of these cases had 
significant pregnancy complications, which is to be expected based on reports from literature. 
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Studies have shown that CPM for trisomy 7 with biparental inheritance is not associated 
with adverse effects on fetal growth (Kalousek et al., 1996).  However, maternal UPD7 is 
associated with severe growth restriction and is found in approximately 10% of cases with 
Russell-Silver syndrome.  Several studies have also confirmed that postnatal growth restriction 
leading to short stature is also a finding of maternal UPD7 (Ledbetter and Engel, 1995; Kalousek 
et al., 1996).  Three of the four cases involved in the study were tested for UPD7 and all three 
showed biparental inheritance. 
Trisomy 7 detected by amniocentesis is generally associated with a good outcome.  For 
example, Hsu et al. (1997) reported eight cases of trisomy 7 mosaicism detected in amniotic 
fluid.  One case was found to have facial asymmetry, mild developmental delay and 
hypomelanosis of Ito at 7 years of age while the other seven cases resulted in normal live births.  
However, no cases of trisomy 7 mosaicism were identified in our study by amniocentesis so no 
correlations to previous data could be made. 
5.2.3 Trisomy 8 
Complete trisomy 8 results in early spontaneous pregnancy loss, but mosaic trisomy 8 is a well-
described syndrome.  The associated features are variable but may include mental retardation, 
dysmorphic facies, skeletal anomalies, congenital heart defects, and kidney malformations.  
Trisomy 8 that is confined to the placenta is relatively common and is generally of mitotic origin 
(Webb et al., 1998).  In addition, cases involving CPM do not appear to present long-term 
consequences to the fetus (Saks et al, 1998).  Saks et al., (1998) reported a case of what appeared 
to be confined placental mosaicism for trisomy 8 mosaicism.  The pregnancy resulted in IUGR 
with catch-up growth during the neonatal period and the infant did not exhibit features of trisomy 
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8 mosaicism.  Based on these findings and previous studies, they suggest that IUGR occurs 
commonly when type II CPM for trisomy 8 is present but postnatal growth and developmental 
are generally normal.  In addition, a normal amniocentesis result after the identification of 
trisomy 8 mosaicism by CVS does not exclude the possibility of phenotypic and neoplastic 
consequences due to cryptic mosaicism.  Chromosome 8 carries two oncogenes, c-myc and c-
mos, which may account for the development of cancer among some patients with trisomy 8 
mosaicism (Saks et al., 1998). 
Our study identified three cases of trisomy 8 mosaicism by CVS.  All three of these cases 
were confirmed as CPM by amniocentesis.  None of these cases were reported to have features 
of trisomy 8 mosaicism, but they all had pregnancy complications.  One case (13) had PROM 
and was induced at 21 weeks due to delayed fetal growth.  This case resulted in neonatal death.  
Another case (14) was delivered prematurely by C-section at 34 weeks, and the last case (12) 
exhibited pre-eclampsia.  PROM, prematurity, and pre-eclampsia were not commonly reported in 
reviewed literature and suggests that trisomy 8 CPM may increase risk for other pregnancy 
complications other than IUGR. 
When trisomy 8 mosaicism is identified by amniocentesis, the resulting infant often 
appears normal.  This is in part due to the fact that the clinical diagnosis of mosaic or non-mosaic 
trisomy is difficult in a newborn (and even more difficult in an aborted fetus) because 
abnormalities are usually subtle (Hsu et al., 1997).  Hsu et al. (1997) reported 14 cases of trisomy 
8 mosaicism detected in amniotic fluid.  One case with 77% trisomy 8 cells was reported to be 
abnormal while the other 13 cases resulted in apparently normal terminations or live births.  Ten 
of the 13 normal-appearing cases had follow-up cytogenetic testing which confirmed the 
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presence of trisomy 8 mosaicism.  This study illustrates the importance of follow-up testing in 
cases of trisomy 8 so that a diagnosis will not be missed. 
Our study identified one case (78) of mosaic trisomy 8 by amniocentesis, which 
contained 16.7% trisomic cells.  No pregnancy complications were indicated but several 
abnormal features were reported. Ultrasound indicated increased nuchal translucency, mild 
ventriculomegaly, and mild hydronephrosis, which resolved.  Features documented at five 
months of age included prominent pillars of philtrum, full lower lip, extra crease on both 
earlobes, and tall stature, but development was reported to be normal.  Follow-up blood analysis 
confirmed the presence of mosaicism, which explains the mild features that are associated with 
trisomy 8 mosaicism.  The fact that this child was examined a few months after birth most likely 
aided in the identification of subtle features.   
There have been no reports of imprinted genes on chromosome 8 (Ledbetter and Engel, 
1995).  A case of paternal UPD8 and a case of maternal UPD8 have been reported, but they both 
had normal growth and development, making it unlikely that there are imprinted genes of major 
effect on chromosome 8 (Robinson, 2001).  No cases of trisomy 8 in this study had UPD8 
testing.   
5.2.4 Trisomy 9 
Trisomy 9 can occur in a mosaic or non-mosaic state and is characterized by growth retardation, 
mental retardation, congenital heart defects, kidney abnormalities, skeletal abnormalities, and 
distinct facial features (Arnold et al, 1995).  In most cases where trisomy 9 is detected by CVS 
but not by amniocentesis, the outcome is normal, but an abnormal outcome can occur (Robinson, 
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2001).  Confined placental mosaicism for trisomy 9 is generally of mitotic origin, which is more 
commonly associated with a good outcome (Wolstenholme, 1996). 
Our study identified three cases (15, 16, 17) of trisomy 9 mosaicism by CVS.  All of 
these cases were found to be CPM through follow-up cytogenetic testing.  One case was 
electively terminated while the other two cases resulted in apparently normal live births.  
Although there were few cases, the generally good outcome supports findings in previous 
studies. 
When trisomy 9 is detected by amniocentesis, the risk for an abnormal outcome is much 
higher.  This statement is supported by Hsu et al (1997).  In their study, they observed 25 cases 
of trisomy 9 mosaicism detected in amniotic fluid.  Of those cases, 14 resulted in abnormal 
offspring (eight had multiple congenital anomalies, seven had facial dysmorphism, four had 
congenital heart disease, three had urogenital abnormalities, three had skeletal problems, and 
three had IUGR).   
In our study, one case (79) was reported to have trisomy 9 mosaicism identified in 
amniotic fluid.  This case was electively terminated.  However, ultrasound indicated a Dandy 
Walker formation, and tissue analysis confirmed fetal mosaicism.  Even though there was only 
one case, the observation of an anomaly on ultrasound further supports the increased risk for 
abnormalities when trisomy 9 mosaicism is present in amniotic fluid. 
Based on cases reported to date, it is unlikely that chromosome 9 is associated with 
imprinting effects (Ledbetter and Engel, 1995).  None of the cases in this study with trisomy 9 
mosaicism had follow-up UPD testing. 
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5.2.5 Trisomy 10 
Complete trisomy 10 is rare and lethal.  There have been five cases reported of liveborn children 
with trisomy 10 mosaicism, and in all cases, the outcome was abnormal (Robinson, 2001).  
Knoblauch et al (1999) suggested that common clinical features include growth retardation, 
feeding problems, failure to thrive, distinct facial features, high arched palate, a long slender 
trunk, cardiac defects, renal, skeletal and central nervous system (CNS) abnormalities, and early 
death.  
Three cases (18, 19, 20) of trisomy 10 mosaicism were observed in our study.  One of 
these cases (20) resulted in IUFD at 14+ weeks.  The other two cases resulted in apparently 
normal live births.  One case (18) was confirmed as confined to the placenta by further testing 
and features noted at birth included mild hypotelorism, epicanthal folds, and a single palmar 
crease.  However, these features were felt to be familial.  The second case did not have further 
testing. 
Trisomy 10 mosaicism is not often found in amniotic fluid.  For instance, Hsu et al. 
(1997) did not identify any cases of trisomy 10 mosaicism in a large case report of chromosomal 
mosaicism detected by amniocentesis.  In our study, no cases of trisomy 10 mosaicism were 
detected in amniotic fluid. 
One case of maternal UPD10 has been reported with no apparent imprinting effect 
(Ledbetter and Engel, 1995).  UPD testing was not performed for any of the trisomy 10 mosaic 
cases in this study. 
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5.2.6 Trisomy 12 
The majority of cases of trisomy 12 detected prenatally have had normal outcomes (Robinson, 
2001).  Data suggests that trisomy 12 is often of mitotic origin, which, again, may explain the 
good outcome (DeLozier-Blanchet et al., 2000).  However, the possibility of neoplastic 
consequences may exist since trisomy 12 is the most frequent chromosomal abnormality in 
chronic lymphocytic leukemia, which is also of mitotic origin (DeLozier-Blanchet et al., 2000).  
Our study identified one case (21) of trisomy 12 mosaicism by CVS.  This case was found to be 
confined to the placenta, and the pregnancy resulted in an apparently normal live birth, which is 
expected based on previous case reports. 
Abnormal outcomes were observed in 6 of 23 (26.1%) cases of trisomy 12 detected in 
amniotic fluid in a large study by Hsu et al (1997).  Of these cases, 10 resulted in live births 
(three had abnormal findings including congenital heart defects and digit anomalies), two ended 
in fetal demise (one was associated with IUGR) and 11 pregnancies were terminated (one was 
reported to have facial dysmorphism and multiple anomalies on autopsy).  Based on this 
information, they suggest that a diagnosis of trisomy 12 mosaicism in amniotic fluid should not 
be taken lightly because the risk of abnormality is significant.  Our study identified one case (80) 
of trisomy 12 mosaicism by amniocentesis.  However, no pregnancy outcome information was 
available and no follow-up testing was performed.  Therefore, no correlation to previous studies 
could be made. 
There have been no reports of imprinted genes on chromosome 12 (Ledbetter and Engel, 
1995).  UPD12 testing was not performed for any of the trisomy 12 mosaicism cases observed in 
this study.   
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5.2.7 Trisomy 13 
Trisomy 13 occurs in approximately 1 in 10,000 live births with mosaic trisomy 13 accounting 
for approximately 5% of these cases (Eubanks et al., 1998).  Individuals with mosaic trisomy 13 
may present with clinical findings ranging from severe mental retardation and multiple 
congenital anomalies to milder mental retardation and physical features.  Prenatal detection of 
mosaic trisomy 13 most often represents confined placental mosaicism but true mosaicism is 
possible (Delatycki et al., 1998).  As an example, Hahnermann and Vejerslev (1997) reported 15 
cases of trisomy 13 mosaicism detected on CVS.  Of these cases, 13 were confined to the 
placenta and resulted in normal outcomes and two were confirmed in the fetus.   
Our study identified one case (22) of trisomy 13 mosaicism by CVS.  Follow-up 
amniocentesis indicated that it was confined to the placenta, and the pregnancy resulted in a 
normal live birth.  The infant was reported to appear normal at two months of age.  This outcome 
further confirms previous studies. 
When trisomy 13 cells are detected in amniotic fluid, it is difficult to predict the severity 
of outcome.  Wallerstein et al (2000) reported 25 cases of trisomy 13 mosaicism diagnosed by 
amniocentesis with 10 cases resulting in an abnormal outcome.  Of these cases, five had multiple 
congenital anomalies, two had IUGR, and three died in utero.  In addition, Delatycki et al (1998) 
reported six cases of trisomy 13 mosaicism detected by amniocentesis with two cases confirmed 
in the fetus.  Both cases presented with low-level fetal mosaicism with no major phenotypic 
effects.  The range of clinical severity most likely depends on the proportion of trisomy 13 cells 
and the way they are distributed throughout the body.  However, based on previous reports, there 
appears to be a poor correlation between the level of abnormal cells in peripheral blood analysis 
and the severity of clinical outcome.  
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In our study, one case (81) of trisomy 13 mosaicism was identified by amniocentesis.  
The result was an apparently normal live birth, and blood analysis indicated a normal karyotype.   
Because outcome can vary and there was only one case, it is difficult to correlate this result to 
previous studies. 
Neither maternal nor paternal UPD13 is associated with an abnormal phenotype so it is 
unlikely that chromosome 13 is associated with imprinting effects (Ledbetter and Engel, 1995).  
UPD testing was performed for one case of trisomy 13 mosaicism that was originally detected by 
CVS.  The results indicated biparental inheritance. 
5.2.8 Trisomy 15 
Complete trisomy 15 is a lethal abnormality.  Trisomy 15 mosaicism detected by CVS is most 
likely confined to the placenta and associated with a normal outcome (Robinson, 2001).  Our 
study identified two cases (23 and 24) of trisomy 15 mosaicism by CVS.  For one case (24), 
amniocentesis indicated that the mosaic cells were confined to the placenta, but pregnancy 
outcome information was not available.  The other case (23) had follow-up amniocentesis, which 
further confirmed mosaicism.  This case resulted in PROM and preterm delivery at 34 weeks.  It 
is possible that the pregnancy complications seen in this case were due to the trisomy 15 
mosaicism. 
True fetal mosaicism for trisomy 15 is rare, but it is associated with a high risk for 
developmental abnormalities when present (Robinson 2001).  Hsu et al. (1997) reported 11 cases 
of trisomy 15 mosaicism detected by amniocentesis.  Of these cases, four resulted in normal live 
births, one was born at term with IUGR and multiple heart defects and died at 13 days, and six 
were terminated (five of these cases had abnormalities).  A higher percentage of abnormal cells 
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in amniotic fluid appeared to correlate with a worse outcome.  No cases in this study were 
identified by amniocentesis, but as previously mentioned, one case was identified by CVS and 
further confirmed by amniocentesis.  No other testing was performed and no abnormalities were 
reported. 
Imprinting defects are known for both maternal and paternal UPD15.  Therefore, UPD 
studies are always suggested when trisomy 15 mosaicism is detected prenatally.  Maternal 
UPD15 is associated with Prader Willi syndrome, and paternal UPD15 is associated with 
Angelman syndrome.  Trisomy 15 mosaicism is usually due to a maternal meiosis error so 
maternal UPD15 is of greater concern.  Both cases of trisomy 15 mosaicism observed in this 
study had UPD testing and both showed biparental inheritance. 
5.2.9 Trisomy 16 
Trisomy 16 is the most commonly occurring trisomy in humans and is thought to occur in more 
than 1% of clinically recognized pregnancies.  Complete trisomy 16 usually results in 
spontaneous abortion during the first trimester.  Therefore, when trisomy 16 is diagnosed 
prenatally in a normally developing fetus, it is almost always mosaic (Robinson, 2001).  In most 
cases of trisomy 16 diagnosed by CVS, the outcome will be good even if the placenta indicates 
complete trisomy.  Adverse outcome is more common when trisomic cells are seen in amniotic 
fluid.  The most common complication when trisomy 16 is diagnosed prenatally is IUGR.  Other 
risks include fetal malformations, maternal hypertension, and fetal or neonatal death.  
Malformations that have been associated with trisomy 16 include heart defects, hypospadias, two 
vessel cord, clinodactyly, and pulmonary hypoplasia.  There is also an increased risk for preterm 
delivery (Yong et al., 2003).   
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Langlois et al. (submitted 2005) compiled follow-up information for 36 cases of trisomy 
16 mosaicism detected on CVS or amniocentesis.  Of these cases, 20 were diagnosed by CVS  
(with normal or unknown amniocentesis result) and showed normal development.  In addition, 
catch-up growth was noted in most cases with IUGR.  Of sixteen cases diagnosed by 
amniocentesis, four cases showed global developmental delay and more than one major 
malformation.   
In our study, three cases (25, 26, 27) of trisomy 16 mosaicism were identified by CVS.  
For one of these cases (26), amniocentesis further confirmed the mosaic karyotype.  The patient 
electively terminated, and tissue analysis confirmed the presence of mosaicism in the fetus.  The 
other two cases had follow-up cytogenetic testing, which confirmed that the mosaicism was 
confined to the placenta.  One case (25) was complicated by pre-eclampsia, IUGR, and preterm 
delivery at 33+ weeks.  No other cases of trisomy 16 mosaicism were identified in amniotic 
fluid.  The fact that both cases of trisomy 16 CPM resulted in pregnancy complications supports 
the findings of previous studies.   
Almost all cases of trisomy 16 mosaicism result from an error in maternal meiosis.  
Fetuses with UPD16 tend to be smaller at birth than fetuses with biparental inheritance, but 
trisomy 16 in the placenta seems to have an adverse effect on growth even in the absence of 
UPD.  Therefore, the consequences of UPD16 are not yet clear (Yong et al, 2003).  One case 
(25) of trisomy 16 mosaicism identified in this study had follow-up UPD16 testing.  Thomas 
(1998) reported that this case indicated biparental inheritance and resulted from an error of 
maternal meiosis. 
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5.2.10 Trisomy 18 
Trisomy 18 is one of the few trisomies that can survive to term in a non-mosaic state.  As a 
result, when trisomy 18 is diagnosed prenatally, the risk for true mosaicism is greater than for 
other trisomies.  However, trisomy 18 can be confined to the placenta and result in a normal birth 
(Robinson, 2001).  For example, Smith et al. (1999) reported 19 cases of mosaic trisomy 18 
detected on CVS of which five were confirmed in the fetus.  In 11 cases of presumed confined 
placental mosaicism, one pregnancy was terminated, one outcome was unknown, and nine 
resulted in normal live births.   
Two cases (28 and 29) of trisomy 18 mosaicism were identified by CVS in our study.  
Both had normal karyotypes in amniotic fluid and resulted in live births.  One case (29) was 
noted to have increased nuchal translucency on ultrasound, which resolved, and was delivered 
prematurely by C-section at 27+ weeks.   It is possible that the increased nuchal translucency 
could have been due to low level mosaicism that was not detected by amniocentesis.   
In a study by Wallerstein et al. (2000), it was found that 54% of cases, involving trisomy 
18 mosaicism detected in amniotic fluid, resulted in an abnormal outcome, including phenotypic 
abnormalities, IUGR, or fetal demise. They reported 31 cases of trisomy 18 mosaicism detected 
by amniocentesis.  Of these cases, three resulted in normal live births, 11 resulted in normal 
abortions, and 17 resulted in abnormal abortions.  Of the abnormal cases, 10 were reported to 
have multiple congenital anomalies, two had dysmorphic facies, three resulted in unexplained 
intrauterine fetal death (IUFD), and two had IUGR.  The risk of abnormal outcome increased 
with detection in fetal blood.   
In our study, two cases (84 and 85) of trisomy 18 mosaicism were detected in amniotic 
fluid.  One case (84) was terminated, and although there was follow-up tissue analysis, the cells 
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did not grow.  This case was reported to have choroids plexus cysts on ultrasound.  The other 
case (85) was reported to have cystic hygroma on ultrasound, but pregnancy outcome could not 
be obtained.  In addition, no further cytogenetic testing was performed.  These cases do not 
provide much information.  However, cystic hygroma is associated with trisomy 18 and may 
indicate some level of trisomy 18 mosaicism in the fetus. 
To date, there have been no reports of imprinted genes on chromosome 18 (Ledbetter and 
Engel, 1995).  None of the trisomy 18 mosaicism cases in this study had follow-up UPD18 
testing. 
5.2.11 Trisomy 20 
Complete trisomy 20 is not viable, and trisomy 20 mosaicism detected by CVS is rare.  Trisomy 
20 mosaicism is more often detected in direct CVS analysis than in CVS cultures, and the 
amniocentesis result and pregnancy outcome is generally normal in these cases (Robinson, 
2001).   
One case (27) of trisomy 20 mosaicism was observed in our study, and trisomy 16 
mosaicism was also present.  This pregnancy resulted in an apparently normal live birth.  Blood 
and tissue analysis indicated normal karyotypes.  
Trisomy 20 is one of the more common mosaic trisomies detected by amniocentesis.  
When trisomy 20 mosaicism is detected in amniotic fluid, the outcome is normal in 90-95% of 
cases.  Abnormal outcomes that have been reported include unexplained fetal demise, IUGR, and 
multiple congenital anomalies (Robinson, 2001).  Wallerstein et al. (2000) reported 152 cases of 
trisomy 20 mosaicism detected in amniotic fluid.  Of these cases, 10 (6.5%) had abnormal 
outcomes, including IUGR, IUFD, hypotonia, multiple congenital anomalies, CNS 
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abnormalities, facial dysmorphism, failure to thrive, and developmental delay.  Robinson et al. 
(2005) reported six additional cases of trisomy 20 mosaicism.  Four cases with low levels of 
trisomy in amniotic fluid were associated with a normal outcome while the other two cases had 
high levels of trisomy in amniotic fluid and had abnormal outcomes (one had developmental 
delay and the other was a stillbirth with IUGR and severe oligohydramnios).  The study also 
further confirmed an association between the level of trisomy and outcome, citing only 4% 
abnormal outcomes when less than 40% trisomic cells were observed.   
Our study identified three cases (86, 87, 88) of trisomy 20 mosaicism in amniotic fluid.  
None of these cases had follow-up cytogenetic testing.  Two of these cases (86 and 87) resulted 
in apparently normal live births while pregnancy outcome was not available for the third case 
(88).  However, case 87 had a low birth weight so the possibility of IUGR is present and case 88 
was reported to have short limbs and duodenal atresia on ultrasound.  The fact that pregnancy 
complications and abnormalities were found for two of the three cases indicates that there is a 
possible risk for adverse outcome. 
UPD20 appears to be rare in trisomy 20 mosaicism.  Due to the limited number of 
reported cases, a conclusion has not been made concerning the possible imprinting effects 
(Robinson et al., 2005).  However, it is thought that maternal imprinting may be associated with 
parathyroid hormone resistance and paternal imprinting may be necessary for embryofetal 
neurological development (Engel, 2003).  None of the trisomy 20 mosaicism cases in this study 
had follow-up UPD testing.  
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5.2.12 Trisomy 21 
Trisomy 21 (Down syndrome) is the most common chromosome abnormality among live births 
with an incidence of 1 in 800.  In general, the features of mosaic Down syndrome are similar to 
those of full Down syndrome.  Features tend to be milder, but the effects can vary depending on 
the level and distribution of trisomic cells.  Therefore, individuals may range from normal to 
having a full expression of Down syndrome.  Associated characteristics include mental 
retardation, distinctive dysmorphic facial features, cardiac anomalies, and duodenal atresia.  In 
addition, generalized edema may be identified prenatally (Robinson, 2001).  It has been difficult 
for studies to predict the outcome of prenatally diagnosed trisomy 21 mosaicism since most 
pregnancies are terminated.  For instance, Sachs et al. (1990) reported four cases of trisomy 21 
mosaicism detected by CVS.  All four pregnancies were terminated and mosaic trisomy 21 was 
confirmed in fetal tissue.   
In our study, one case (30) of complete trisomy 21 that was mosaic for monosomy X was 
identified by CVS.  This case was terminated and the karyotype was confirmed in fetal tissues.  
No other information was available. 
Wallerstein et al. (2000) identified 97 cases of trisomy 21 mosaicism detected by 
amniocentesis and 49 (51%) had abnormal outcomes.  Of these cases, two resulted in normal live 
births, 41 resulted in therapeutic abortions that appeared normal, six resulted in abnormal live 
births, and 43 resulted in abortions that appeared abnormal.  Of the six abnormal live births, five 
cases had Down syndrome facies and associated findings and one had an isolated congenital 
heart defect.  Of the 43 abnormal abortions, 18 cases had Down syndrome facies, 15 had 
multiple congenital anomalies, five resulted in IUFD, four had IUGR, and one had an isolated 
congenital heart defect.  This study further illustrates the high proportion of pregnancy 
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terminations associated with a trisomy 21 result and also indicates that the majority of cases 
detected by amniocentesis are associated with some features of Down syndrome. 
Six cases (89-94) of trisomy 21 mosaicism detected by amniocentesis were observed in 
our study.  Three of these cases (90, 92, 93) had results that were confirmed in the fetus by 
follow-up cytogenetic testing while one (91) was not found in the fetus and two (89, 94) did not 
have further testing.  Two cases (90 and 93) were terminated, and one (90) was reported to have 
a Simian crease on pathology report.  The other four cases resulted in live births.  One (89) was 
reported to have Down syndrome but no specific features were documented.  One (92) had distal 
axial triradii, and another (94) had increase nuchal translucency on ultrasound.  One case (91) 
had no documented features of Down syndrome.  These results illustrate the range of clinical 
outcomes that can be seen with mosaic trisomy 21. 
Uniparental disomy for chromosome 21 is not thought to have any phenotypic effect 
(Robinson, 2001).  None of the cases in this study involving trisomy 21 had follow-up UPD21 
testing. 
5.2.13 Trisomy 22 
Trisomy 22 is the second most common autosomal trisomy found among spontaneous abortions, 
accounting for 3-5%.  Complete trisomy 22 may survive to birth, but it is very rare (Robinson, 
2001).  Clinical findings that are associated with complete trisomy 22 include IUGR, 
microcephaly, hypertelorism, epicanthal folds, hypoplastic or low-set ears, midface hypoplasia, 
hypoplastic distal phalanges, and genitalia anomalies in males (Bacino et al., 1995).  Other 
reported findings include cleft palate, cardiac and/or renal anomalies and anal atresia/stenosis.  
When prenatally diagnosed mosaic trisomy 22 is confined to the placenta, the outcome can be 
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normal, but there is a risk for low birth weight. The outcome is variable when confirmed in the 
fetus.  The behavior of trisomy 22 CPM appears to be similar to trisomy 16 CPM (Robinson, 
2001).   
Seven cases of trisomy 22 mosaicism detected by CVS with low or absent levels of 
trisomy in follow-up amniocentesis have been reported to date.  Of these, three cases had a 
normal outcome, three had IUGR, and one had IUGR and some anomalies.  All of the cases were 
of maternal meiotic origin (Robinson, 2001).  One case (31) of trisomy 22 mosaicism was 
detected by CVS in our study.  Follow-up amniocentesis indicated a normal karyotype, but 
pregnancy outcome information could not be obtained. 
Six cases of mosaic trisomy 22 detected in amniotic fluid have been reported in literature.  
IUGR was common but four of the six cases were not reported to have any obvious anomalies at 
birth (Robinson, 2001).  No cases of trisomy 22 mosaicism detected by amniocentesis were 
identified in our study. 
UPD22 is not known to be associated with imprinting effects, and maternal UPD22 has 
been found in normal individuals.  It should be noted, however, that all five cases of maternal 
UPD22 associated with trisomy detected prenatally or at birth did have low birth weight 
(Robinson, 2001).  UPD testing was not performed for the trisomy 22 mosaic case in our study. 
5.2.14 Trisomy X/Y 
A small number of 47,XXX, 47,XXY, and 47,XYY cases have been detected by CVS and 
confirmed in fetal tissues, and follow-up information is limited.  Information pertaining to the 
outcome of mosaic CVS cases is also limited, especially for 47,XYY mosaicism (Smith et al., 
1999).  Smith et al. (1999) confirmed 47,XXX mosaicism for 2 of 4 cases and 47,XXY 
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mosaicism for 1 of 3 cases.  Sex chromosome abnormalities that are confined to the placenta 
have not been closely associated with adverse pregnancy outcome (Wolstenhome et al., 1994).   
Our study included three cases (47-49) with a 47,XXY/46,XY result by CVS.  All three 
cases were confirmed in the fetus by follow-up cytogenetic testing and resulted in normal live 
births.  However, one case (48) was complicated by a persistent fetal intraabdominal cyst and 
fetal tachycardia.  One case with a 48,XXX,+7/46,XX CVS result was also observed.  As 
previously mentioned, amniocentesis indicated a normal karyotype, and the pregnancy resulted 
in a live birth.  
In addition, four (120, 121, 124, and 125) cases with a 47,XXY/46,XY result were 
identified by amniocentesis.  One of these cases (124) was confirmed in the fetus by blood 
analysis while the other three did not have follow-up testing.  Three (120, 121, and 124) cases 
resulted in apparently normal live births while pregnancy outcome information was not available 
for the third case.  One case of 47,XYY/46,XY (126) was also detected in amniotic fluid.  This 
case was one of twins, and the mother did not want to know which twin was affected.  Follow-up 
blood analysis confirmed the presence of mosaicism in the fetus.  The pregnancy resulted in 
preterm delivery at 35+ weeks, but both twins were reported to appear normal.  The preterm 
delivery could have been the result of a twin pregnancy (twin pregnancies have a tendency to 
deliver prematurely).  These results indicate that trisomies involving choromosomes X and Y 
tend to have good outcomes.  However, complications could still present at puberty so follow-up 
testing would be helpful. 
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5.2.15 Monosomy 21 
Nine cases of monosomy 21 have been described to date.  Of these cases, six resulted in live 
births and three were spontaneously aborted.  However, many of these cases were reported in the 
late 1970’s and early 1980’s when banding techniques were not as high quality.  It is possible 
that some of these cases were chromosome 21 translocations instead of true monosomy 21 
(Robinson, 2001).  One case (95) of monosomy 21 was detected by amniocentesis in this study.  
No follow-up testing was performed and no pregnancy outcome information was available. 
5.2.16 Monosomy X 
45,X (Turner syndrome) is a common cause of early pregnancy loss, accounting for about 7%, 
and is present in 1-2 per 10,000 live births.  Approximately 30% of Turner syndrome patients are 
mosaic with a 45,X cell line and either a normal cell line or one containing a rearranged X 
chromosome (Hook and Warburton, 1983).  Individuals with mosaic monosomy X will generally 
have a milder phenotype than those with complete monosomy X.  It has been determined that the 
monosomy X is maternally derived in 80% of cases (Robinson, 2001).   
Sachs et al. (1990) reported seven cases of monosomy X mosaicism detected by CVS.  
Six cases involved a normal female cell line and one involved a normal male cell line.  Of these 
cases, six resulted in normal outcomes and one was terminated due to lack of growth.  This study 
indicates that the detection of monosomy X mosaicism by CVS is generally associated with a 
good outcome. 
Nine cases (33-41) with a 45,X/46,XX CVS result were observed in our study.  Six of 
these cases (33, 34, 35, 37, 38, and 41) resulted in apparently normal live births, two (36 and 40) 
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resulted in spontaneous abortions, and one (39) pregnancy was terminated.  Six of the nine cases 
had follow-up cytogenetic testing.  Four (33, 34, 35, 36) were found to have normal karyotypes 
while two cases (40 and 41) showed confirmed mosaicism in the fetus.  No features of Turner 
syndrome were reported for either of these cases.  One case (76) of 45,X/46,X,+i(X)(q10) was 
also observed.  This case was terminated and no follow-up testing was performed.  Five cases 
(42-46) with a 45,X/46,XY CVS result were also observed in this study.  One case (46) had a 
follow-up amniocentesis, which indicated a normal karyotype.  The other cases did not have 
follow-up testing.  All five cases resulted in apparently normal live births.  These results also 
indicate that mosaicism involving monosomy X that is detected by CVS will most likely have a 
normal result.   
Eighteen cases (96-113) with a 45,X/46,XX result, detected by amniocentesis, were also 
observed in this study.  Of these cases, nine resulted in live births, one (97) resulted in a 20 week 
fetal demise, one (109) was terminated, two (101 and 102) were still in utero as of March 25, 
2006, and pregnancy information was not available in five cases (96, 98, 99, 104, and 111).  Of 
the nine liveborn cases, three had pregnancy complications and/or abnormalities.  One case (100) 
reportedly had coarctation of the aorta, and another case (107) was reported to have a 
diaphragmatic hernia, mild edema, hyperconvex nails, and posteriorly rotated ears. Also, case 
113 was induced because of hypertension, indicating the possibility of the beginnings of pre-
eclampsia.  In addition, case 97, which resulted in fetal demise, was reported to have cystic 
hygroma on ultrasound.  Seven of the eighteen cases had follow-up testing.  Two (96 and 106) 
indicated a normal karyotype, two (97 and 112) indicated a 45,X karyotype, and three (107, 108, 
110) confirmed a mosaic karyotype.  Although information was unavailable for several patients, 
these results show that a 45,X/46,XX karyotype detected in amniotic fluid can often result in 
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pregnancy complications and features of Turner syndrome.  Complications could also occur at 
puberty so follow-up evaluations would provide more information for these outcomes. 
Five cases (114-118) with a 45,X/46,XY amniocentesis result were also observed.  Of 
these cases, three (115, 116, and 118) resulted in apparently normal live births, one (114) was 
terminated, and one (117) had no available pregnancy outcome information.  One (115) of the 
liveborn cases was reported to have choroid plexus cysts and normal genitalia on ultrasound.  
Four cases had follow-up cytogenetic testing.  Testing indicated a normal karyotype for two 
cases (114 and 115) and a mosaic karyotype for the other two cases (116 and 118).  A case (142) 
with a 45,X/46,X,i(Y)(p10) result was also observed.  Increased nuchal translucency was 
documented on ultrasound, and it resulted in an apparently normal live birth.  These results 
indicate a generally good outcome for 45,X/46,XY mosaic cases.  However, problems may 
develop at puberty so a follow-up would be helpful for further information. 
5.2.17 Structural Aberrations 
True mosaicism involving autosomal structural aberrations other than small supernumerary 
chromosomes is rare but does occur.  These cases account for approximately 10% of all 
prenatally diagnosed cases of chromosome mosaicism (Hsu et al., 1996).  Clinical implications 
vary depending on the type of structural abnormality.  Hsu et al. (1996) studied various types of 
autosomal structural aberrations detected in amniotic fluid.  From their data, they made several 
karyotype – phenotype correlations.  Their data indicated that mosaic cases for a balanced 
structural rearrangement, including reciprocal translocations, Robertsonian translocations, and 
inversions, were usually associated with a normal phenotype.  This was not true for cases of 
mosaicism involving an unbalanced structural abnormality.  The overall risk for an abnormal 
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outcome in an case with an unbalanced structural abnormality (excluding those involving i(20q) 
and +i(12p)) was estimated to be 40.4%.  All cases involving i(20q) resulted in a normal 
outcome, and almost all cases involving +i(12p), which is associated with Pallister-Killian 
syndrome, were associated with an abnormal outcome. 
In our study, nine cases involving autosomal structural abnormalities were observed by 
CVS.  One of these cases (67) was a balanced reciprocal translocation.  This case had a normal 
karyotype in amniotic fluid and resulted in a normal live birth.  The other eight cases had 
unbalanced structural aberrations and of these cases, seven had follow-up cytogenetic testing.  
Four cases (68, 70, 72 and 74) had normal karyotypes, two (69 and 71) had confirmed 
mosaicism, and one case (73) indicated complete structural aberration.  Four cases resulted in 
normal live births, one (73) was electively terminated, and two had pregnancy complications 
and/or reported anomalies.  One case (71) resulted in preterm delivery at 22 weeks and neonatal 
death shortly after birth.  The mosaic karyotype was confirmed by amniocentesis and tissue 
analysis, and the fetus was reported to have dysmorphic features consistent with Pallister-Killian 
syndrome.  Another case (70) was reported to have increased nuchal translucency on ultrasound.  
This patient is still pregnant so it is not known if there will be pregnancy complications. 
Of the amniocentesis cases in this study, three had autosomal structural aberrations and 
all were unbalanced.  Two of the cases were terminated (136 and 137) and one case (134) did not 
have available pregnancy outcome information.  For case 136, ultrasound indicated a 
diaphragmatic hernia and tissue analysis confirmed the mosaic karyotype in the fetus.  This case 
was considered to be consistent with Pallister-Killian syndrome.  For case 137, no abnormalities 
were reported and tissue analysis indicated a normal karyotype.  These results support the 
finding that unbalanced structural rearrangements are more likely to cause complications than 
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balanced rearrangements when mosaicism is diagnosed prenatally.  However, an unbalanced 
rearrangement can result in a normal outcome, particularly if the aberration is confined to the 
placenta. 
5.2.18 Supernumerary Markers 
A marker chromosome is a structurally abnormal chromosome that cannot be identified by 
routine cytogenetics, and examples include unidentified rings, derivatives, dicentrics, and minute 
chromosomes.  The risk for phenotypic abnormalities due to a marker chromosome depends on 
inheritance, mode of ascertainment, chromosomal origin, and the morphology, content, and 
structure of the marker.  When markers are inherited directly from a phenotypically normal 
parent, there are usually no phenotypic consequences, but there can be exceptions, such as 
imprinting effects from UPD or low-level, tissue-specific mosaicism for the marker in a parent 
without phenotypic manifestations (Graf et al., 2005).   
The first major study to offer general risk figures for marker chromosomes was 
conducted by Warburton (1991).  This study suggested, based on 133 prenatal cases involving 
marker chromosomes, an overall risk of 13% for phenotypic abnormalities in prenatally obtained 
de novo cases of supernumerary marker chromosomes.  However, fluorescence in situ 
hybridization (FISH) technology was not available at the time, which limited their ability to fully 
characterize the markers.  A later study by Crolla (1998) confirmed that most marker 
chromosomes originate from acrocentric chromosomes (13, 12, 15, 21, and 22), and that these 
cases were much less likely to be associated with a phenotypic abnormality. 
In a recent study by Graf et al. (2005), the risk for a phenotypic abnormality was 
estimated to be 26% for a de novo supernumerary marker diagnosed prenatally with no other 
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defining information.  This risk was reduced to 18% if high resolution ultrasound studies were 
normal.  In addition, the study revealed that there is a 4% risk for phenotypic affects in 
pregnancy if one of the parents was found to have the marker chromosome (in a non-mosaic 
state). 
In our study, 14 cases involving supernumerary marker chromosomes were detected by 
CVS.  Ten of these cases were apparently de novo with no identified origin.  Eight of these cases 
resulted in apparently normal live births (although one had increased nuchal translucency on 
ultrasound), one resulted in a live birth that delivered prematurely at 29 weeks and was 
complicated by chorioamnionitis, and one was electively terminated.  Five of these cases had 
follow-up cytogenetic testing which revealed a normal karyotype while the other five cases had 
no additional testing.  Two additional cases, which were also detected by CVS, were later 
confirmed in amniotic fluid and the chromosome origin was determined (derivatives of 17 and 
Y).  Both cases resulted in apparently normal live births.  Lastly, two cases identified by CVS 
were determined to be of maternally inherited.  One resulted in an apparently normal live birth 
while pregnancy information was not available for the second.  Neither had additional testing. 
In addition, this study observed six cases involving supernumerary markers, which were 
diagnosed by amniocentesis.  One case (132) also involved mosaicism for monosomy X.  This 
case resulted in a live birth that was noted to have mild edema of the hands and feet.  Blood 
analysis confirmed the mosaic karyotype while tissue indicated a 45,X karyotype.  Two cases 
involved markers that were identified (inv dup(13)(p10) and dup(21q11.2)).  One resulted in a 
live birth with no documented anomalies (inv dup(13)(p10)) and there was no pregnancy 
outcome information available for the second.  Neither case had follow-up cytogenetic testing.  
The chromosomal origins were determined for the three remaining cases.  One case was derived 
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from chromosome 22.  No pregnancy outcome information was available and no follow-up 
cytogenetic testing was performed.  A second case was derived from chromosome 6.  This case 
resulted in a live birth with normal appearance and development reported at 15 months of age.  
The third case was derived from chromosome 7 and was terminated.  Before termination, the 
placenta was documented to have ruptured membranes and both twins, who were 
monochorionic, had abnormalities.  One twin (the “pump twin”) had a hypoplastic left heart and 
left lung aplasia while the second twin (the “acardiac twin”) was noted to be amorphous.  Fetal 
mosaicism for these last two cases was confirmed in follow-up testing. 
The results from our study seem to show an overall good outcome for prenatally 
diagnosed marker chromosomes, especially when they are confined to the placenta.  However, 
abnormal outcome associated with a chromosome 7 marker shows that the effects from marker 
chromosomes can be quite severe.   
5.2.19 Tetraploidy 
It is not uncommon to detect tetraploid cells in prenatal diagnosis.  These cases are generally 
considered to be at no increased risk for adverse outcomes and are not reported.  Therefore, there 
are very few clinical reports of individuals with tetraploidy mosaicism, and they were most likely 
reported when abnormalities were present (probably by coincidence) (Robinson, 2001).  Two 
cases (64 and 65) with a 92,XXXX/46,XX result were detected by CVS in this study.  One of 
these cases resulted in spontaneous abortion, and tissue analysis indicated a normal karyotype.  
The other case resulted in an apparently normal live birth that delivered prematurely at 36+ 
weeks.  One case (66) with a 92,XXYY/46,XY result was also detected by CVS.  This case had a 
follow-up amniocentesis with a normal karyotype and resulted in an apparently normal live birth.  
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No tetraploid cases were observed by amniocentesis.  These results further support that 
tetraploidy that is confined to the placenta generally has a normal outcome.  However, one of our 
cases was delivered prematurely, may or may not be due to tetraploidy mosaicism. 
 
5.3 SUMMARY 
One specific aim of this study was to review cases of mosaicism and uniparental disomy (UPD) 
detected by chorionic villus sampling (CVS) and amniocentesis performed during the time 
period 1991-2005 to determine if rates of mosaicism and true fetal mosaicism correlate with 
literature.  The CVS cases had a mosaicism rate of 1.65%, and the amniocentesis results had a 
mosaicism rate of 0.38%.  Both rates were comparable to those reported in previous studies.  The 
rate of true fetal mosaicism for CVS cases was 23.6% and was 60.7% for amniocentesis cases.  
Both of these rates are also comparable to literature. 
 Another specific aim was to evaluate follow-up information obtained through Magee-
Womens Hospital, including pregnancy outcome, pregnancy complications, abnormal 
characteristics, and additional testing.  This information was obtained through the GIS database 
and by calling the offices of patients’ gynecologists/obstetricians.  Pregnancy outcome 
information was obtained for 73 of 76 (96.1%) CVS cases and 43 of 59 (72.9%) amniocentesis 
cases.  The three CVS cases with unavailable information were considered lost to follow-up.  
The 16 amniocentesis cases with unavailable information were either lost to follow-up or were 
samples that were obtained from outside practices.  The samples from outside practices did not 
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receive counseling at Magee-Womens Hospital, and therefore, information was not available for 
further contact. 
 A third specific aim was to conduct further follow-up in order to obtain more information 
pertaining to long-term phenotypic effects.  This part of the study required IRB approval, and 
while approval was obtained, patients were not contacted as of March 25, 2006.  However, the 
opportunity to gain further information through contacting patients is available and will be 
performed in the near future. 
 The last specific aim was to analyze the findings to attempt karyotype-phenotype 
correlations.  This study found mosaic results involving trisomy for chromosomes 2, 7, 8, 9, 10, 
12, 13, 15, 16, 18, 20, 21, 22, X, and Y.  In addition, there was monosomy for chromosomes 21, 
22, and X, tetraploidy, structural aberrations, and supernumerary marker chromosomes.  
Pregnancy complications and documented features and anomalies were reported for each type of 
chromosomal mosaicism and compared to other cases reported in literature.  However, further 
information regarding development and features that manifest as a child gets older would 
provide more information and allow for better karyotype-phenotype correlations. 
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6.0  CONCLUSIONS 
Chromosomal mosaicism, when detected prenatally, complicates genetic counseling as 
phenotypic outcome can vary depending on the chromosome involved and the level of 
mosaicism that is present in the fetus.  In addition, UPD and/or cryptic mosaicism, which can be 
missed by routine cytogenetic testing, could cause an abnormal outcome.  Although several large 
studies have provided some information pertaining to mosaicism for different types of 
abnormalities, much is still unknown and long-term follow-up information is limited.   
Based on the information provided from this study, it is apparent that most cases of 
prenatally diagnosed mosaicism result in a normal outcome but more information is needed 
regarding long term consequences.  This study will be continued in order to gain more 
information about our cases.  In addition, all cases of mosaicism detected by CVS or 
amniocentesis should have follow-up cytogenetic testing, including amniocentesis for CVS cases 
and tissue and blood analysis for all cases, in order to determine if the result represents true 
mosaicism.  One suggestion is that samples of foreskin from males after circumcision could be 
used because these samples may provide a more information in addition to the term placenta and 
cord blood that is currently being used for analysis.  Obtaining information pertaining to 
pregnancy and delivery complications through routine follow-up should also be continued and 
maintained.  Also, any cases involving chromosomes that are known to have imprinting affects 
should have testing for UPD. 
Future studies could include a prospective study that would obtain consent for the 
ascertainment of medical records and contact for future follow-up at the time of prenatal 
diagnosis.  This would eliminate the complications associated with obtaining consent years after 
the procedure was performed.  In addition, several of the cases in our study with a trisomy 8 
mosaic result had pregnancy complications, including PROM, preterm delivery, and pre-
eclampsia.  Trisomy 8 mosaicism has not been associated with an increased risk for pregnancy 
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complications in literature but our findings may indicate the need for future studies to investigate 
this possible association.  Also, a match control study could be performed to examine the 
frequency of preterm labor and IUGR to determine if the rate is higher among patients with a 
mosaic result. 
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